Content without topic

LCN Consensus Statement on SMD Webinar – Pakistan

Fouzia Sadiq,

Quratul Ain,

Madeeha Khan,

Kausik Ray,

Stefano Romeo

June 16, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN Consensus Statement on SMD Webinar – Lithuania

Sigita Glaveckaite,

Zaneta Petrulioniene,

Egidija Rinkuniene,

Stefano Romeo,

Kausik Ray

June 16, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN Consensus Statement on SMD Webinar – Czech Republic

Michal Vrablik,

Stefano Romeo,

Kausik Ray,

Lale Tokgözoğlu,

Jan Pit'ha

June 11, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

Newborn Screening for FeFH and FoFH using dried blood spots

Amy L Peterson

May 1, 2026 | Screening for FH, Paediatric Lipid Working Group

LCN Consensus Statement on SMD Webinar – Georgia

Tea Gamezardashvili,

Kausik Ray,

Stefano Romeo,

Tamar Avaliani

May 1, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN Consensus Statement on SMD Webinar – Estonia

Kausik Ray,

Stefano Romeo,

Helen Ilumets,

Martin Serg,

Margus Viigimaa

April 30, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN Consensus Statement on SMD Webinar – Italy

Kausik Ray,

Stefano Romeo,

Luca Fabris

April 29, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN Consensus Statement on SMD Webinar – Uzbekistan

Kausik Ray,

Stefano Romeo,

Jeanine Roeters van Lennep,

Aleksandr Shek,

Khurshid G Fozilov,

Nigora Srozhidinova

April 28, 2026 | Webinars on-demand, LCN Webinars, Lipid Clinic Network

Hot topics in nutrition

Lene F. Andersen,

Stine M. Ulven,

Kirsten Holven

April 23, 2026 | Webinars on-demand

LCN Consensus Statement on SMD Webinar – Iraq

Mutaz Al-Khnifsawi,

Jeanine Roeters van Lennep,

Kausik Ray,

Stefano Romeo,

Barham Sahib

April 23, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN Consensus Statement on SMD Webinar – Portugal

Alberto Mello e Silva,

Francisco Araujo,

Kausik Ray,

Stefano Romeo,

Marianne Benn,

Joana Louro

April 21, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN Consensus Statement on SMD Webinar – Kazakhstan

Kausik Ray,

Stefano Romeo,

Makhabbat Bekbossynova,

Vitaliy Pavlov,

Marianne Benn

April 16, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Russia

Marianne Benn,

Marat Ezhov,

Lale Tokgözoğlu,

Asiiat Alieva

April 14, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN Consensus Statement on SMD Webinar – Colombia

Luz Clemencia Zárate-Correa,

Kausik Ray,

Jannes Buelvas,

Jorge Tejada,

Carlos Sanchez

April 10, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

Omega-3 fatty acids – from basics to clinic

Katariina Öörni,

Peder Langeland Myhre,

Marianne Benn

April 9, 2026 | Webinars on-demand

LCN Consensus Statement on SMD Webinar – Latvia

Kausik Ray,

Stefano Romeo,

Gustavs Latkovskis,

Sanda Jegere

April 2, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

Diet for prevention and management of CVD

Ulf Risérus,

Kirsten Holven,

Evangelos Liberopoulos

March 26, 2026 | Webinars on-demand

LCN 2025 Guidelines Update Webinar – Denmark

Marianne Benn,

Christian Bork,

Berit Storgaard Hedegaard

March 18, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

Webinar on Homozygous Familial Hypercholesterolemia Management (3/3) – FH in women – Part 2/2

Lale Tokgözoğlu,

Liam Brunham,

Meral Kayikcioglu

February 19, 2026 | HoFH Awareness Day, Rare Disease Day, Webinars on-demand

LCN 2025 Guidelines Update Webinar – Lithuania

Zaneta Petrulioniene,

Sigita Glaveckaite,

Jeanine Roeters van Lennep,

Børge Nordestgaard,

Ulrich Laufs,

Egidija Rinkuniene

February 19, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Spain

Luis Masana,

Lina Badimon,

José López Miranda

February 11, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Portugal

Alberto Mello e Silva,

Francisco Araujo,

Alberico L. Catapano,

Carlos Aguiar,

Marianne Benn

February 9, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Argentina

Pablo Corral,

Augusto Lavalle Cobo,

Lale Tokgözoğlu

February 9, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Egypt

Ashraf Reda,

Ahmed Shawky Elserafy,

Ulrich Laufs,

Jeanine Roeters van Lennep,

Ahmed Bendary

February 6, 2026 | Webinars on-demand, LCN Webinars, Lipid Clinic Network

Webinar on Homozygous Familial Hypercholesterolemia Management (2/3) – FH in women – Part 1/2

Kirsten Holven,

Jeanine Roeters van Lennep,

Marianne Benn

February 5, 2026 | Rare Disease Day, HoFH Awareness Day, Webinars on-demand

LCN 2025 Guidelines Update Webinar – Pakistan

Fouzia Sadiq,

Serajuddaula Syed,

Madeeha Khan,

Quratul Ain

February 2, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Japan

Mariko Harada-Shiba,

Hayato Tada,

Børge Nordestgaard,

Masayuki Yoshida

February 2, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Kazakhstan

Vitaliy Pavlov,

Zaure Ormakhanova,

Shoaib Afzal,

Ulrich Laufs,

Makhabbat Bekbossynova

January 29, 2026 | LCN Webinars, Webinars on-demand, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Colombia

Karen Feriz-Bonelo,

Børge Nordestgaard,

Angel Alberto Garcia-Peña,

Luz Clemencia Zárate-Correa

January 28, 2026 | Webinars on-demand, LCN Webinars, Lipid Clinic Network

Webinar on Homozygous Familial Hypercholesterolemia Management (1/3) – Implementing current guidance

Marina Cuchel,

Evangelos Liberopoulos,

Stefano Romeo

January 22, 2026 | Rare Disease Day, HoFH Awareness Day, Webinars on-demand

LCN 2025 Guidelines Update Webinar – Greece

Alexandros Tselepis,

Evangelos Liberopoulos,

Konstantinos C. Koskinas,

Charalambos Vlachopoulos

January 19, 2026 | Webinars on-demand, LCN Webinars, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Luxembourg

Marianne Becker,

Ulrich Laufs,

Dirk Droste,

Carine de Beaufort

January 8, 2026 | Webinars on-demand, LCN Webinars, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Bosnia & Herzegovina

Børge Nordestgaard,

Belma Pojskic,

Lamija Ferhatbegovi´c,

Elnur Smajić

December 11, 2025 | Webinars on-demand, LCN Webinars, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Iraq

Mutaz Al-Khnifsawi,

Khalid Al-Jumaily,

Azad Haleem,

Foaad Shaghee Alfertossy,

Børge Nordestgaard

November 20, 2025 | Webinars on-demand, LCN Webinars, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Uzbekistan

Aleksandr Shek,

Khurshid G Fozilov,

Andrey R Kim,

Børge Nordestgaard,

Shoaib Afzal,

Lale Tokgözoğlu

November 19, 2025 | Webinars on-demand, LCN Webinars, Lipid Clinic Network

LCN 2025 Guidelines Update Webinar – Georgia

Tea Gamezardashvili,

Nino Svanidze,

Børge Nordestgaard

November 16, 2025 | Webinars on-demand, LCN Webinars, Lipid Clinic Network

Ultraprocessed food & the Nordic diet in the context of CVH

Jacob Christensen,

Ursula Schwab,

Kirsten Holven

November 13, 2025 | Webinars on-demand

LCN 2025 Guidelines Update Webinar – Norway

Kirsten Holven,

Elisabeth Vesterbekkmo,

Kjetil Retterstøl,

Børge Nordestgaard

October 30, 2025 | Webinars on-demand, LCN Webinars, Lipid Clinic Network

Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots.

Amy L Peterson,

Vanessa Horner,

Michael R Lasarev,

Xiao Zhang,

Steve Humphries,

Robert D Steiner,

Megan Benoy,

Jessica Tumolo,

Patrice K Held,

Xiangqiang Shao

October 29, 2025 | Screening for FH, Publication, Paediatric Lipid Working Group

LCN 2025 Guidelines Update Webinar – Brazil

Sergio Kaiser,

Fabiana Rached,

André Zimerman,

Alberico L. Catapano

October 23, 2025 | Webinars on-demand, LCN Webinars, Lipid Clinic Network

EAS/ESC Guidelines: Combination therapies – guideline updates and clinical case

Jeanine Roeters van Lennep,

Ulrich Laufs

October 22, 2025 | Webinars on-demand

Clinical staging to guide management of metabolic disorders and their sequelae: A European Atherosclerosis Society consensus statement

Kausik Ray,

Stefano Romeo

October 21, 2025 | Webinars on-demand

Pregnancy and breastfeeding in FH

Kirsten Holven

October 17, 2025 | HoFH Awareness Day, Webinars on-demand, Paediatric Lipid Working Group

Universal paediatric screening for FH – pros & cons

Steve Humphries

October 17, 2025 | HoFH Awareness Day, Webinars on-demand, Paediatric Lipid Working Group

EAS/ESC Guidelines: Lipoprotein(a) – guideline updates and clinical case

Konstantinos C. Koskinas,

Lale Tokgözoğlu

September 29, 2025 | Lp(a) Awareness Day, Webinars on-demand

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: What’s new and what do the experts say?

Børge Nordestgaard,

Jeanine Roeters van Lennep,

Lale Tokgözoğlu

August 30, 2025 |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

Kausik Ray,

Francois Mach,

Jeanine Roeters van Lennep,

Lale Tokgözoğlu,

Lina Badimon,

Marianne Benn,

Christoph Binder,

Alberico L. Catapano,

Guy De Baker,

Brian Ference,

Ian Graham,

Ulf Landmesser,

Ulrich Laufs,

Børge Nordestgaard,

Konstantinos C. Koskinas,

Colin Baigent,

Victoria Delgado,

Natalia Fabin,

Borislava Mihaylova,

Dimitrios J. Richter,

Marc S. Sabatine

August 29, 2025 | Publication, Guideline

2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidemias – Advancing evidence-based care through innovation

Florian Kronenberg,

Kausik Ray,

Jan Borén

August 29, 2025 | Commentaries, Publication

Cardiovascular kidney metabolic syndrome

Meral Kayikcioglu,

Sergio Kaiser,

Fabiana Rached

August 26, 2025 | Webinars on-demand, EAS-LatAm webinar series

Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double- Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial

Albert Wiegman,

Amy L Peterson,

Robert Hegele,

Eric Bruckert,

Anja Schweizer,

Anastasia Lesogor,

Yibo Wang,

Joep Defesche

June 25, 2025 | Other, Paediatric Lipid Working Group

Proposal of a Familial Hypercholesterolemia Pediatric Diagnostic Score (FH-PeDS).

Jan Kafol,

Beatriz Miranda,

Rok Sikonja,

Jaka Sikonja,

Albert Wiegman,

Ana Margarida Medeiros,

Ana Catarina Alves,

Tomas Freiberger,

Barbara Hutten,

Matej Mlinarič,

Tadej Battelino,

Steve Humphries,

Mafalda Bourbon,

Urh Groselj

June 20, 2025 | Screening for FH, Publication, Paediatric Lipid Working Group

The essential role of sex and gender in atherosclerosis research: A statement from the Editorial Board of Atherosclerosis and Executive Committee of the European Atherosclerosis Society

Jeanine Roeters van Lennep,

Katariina Öörni,

Christoph Binder,

Florian Kronenberg,

Ziad Mallat,

Paolo Raggi,

Marianne Benn,

Shoaib Afzal,

Kirsten Holven,

Meral Kayikcioglu,

Ulrich Laufs,

Evangelos Liberopoulos,

Kausik Ray,

Børge Nordestgaard,

Jan Borén

June 11, 2025 | Commentaries, Publication

Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement

Stefano Romeo,

Antonio Vidal-Puig,

Mansoor Husain,

Rexford Ahima,

Arca Marcello,

Deepak Bhatt,

Anna Mae Diehl,

Luigi Fontana,

Roger Foo,

Gema Fruhbeck,

Julia Kozlitina,

Eva Lonn,

Francois Pattou,

Jogchum Plat,

Susan Quaggin,

Paul Ridker,

Mikael Rydén,

Nicola Segata,

Katherine Tuttle,

Subodh Verma,

Jeanine Roeters van Lennep,

Marianne Benn,

Christoph Binder,

Oveis Jamialahmadi,

Rosie Perkins,

Alberico L. Catapano,

Lale Tokgözoğlu,

Kausik Ray

May 7, 2025 | Publication, Consensus paper

A Novel ANGPTL4 Inhibitory Antibody Safely Lowers Plasma Triglycerides And Remnant Cholesterol In Humans

Ethan Weiss

May 7, 2025 | Late Breaker Session: Clinical

Clinical Staging To Guide Actionable Management Of Systemic Metabolic Disorders And Their Sequelae: A European Atherosclerosis Society Consensus Statement

Stefano Romeo

May 7, 2025 | Late Breaker Session: Clinical

Fixed-dose Combination Of Obicetrapib And Ezetimibe For LDL-C Reduction: A Phase 3 Randomized Trial

Steven Nissen

May 7, 2025 | Late Breaker Session: Clinical

Lipoprotein(a) And Recurrent Atherosclerotic Cardiovascular Disease Events By Sex And Race/ethnicity And Use Of Ldl Cholesterol Lowering Therapy: A Cohort Study From The Us Family Heart Database

Børge Nordestgaard

May 7, 2025 | Late Breaker Session: Clinical

Safety And Efficacy Of Obicetrapib In Patients At High Cardiovascular Risk

Stephen Nicholls

May 7, 2025 | Late Breaker Session: Clinical

Zodasiran (ARO-ANG3), An Investigational RNAi Therapeutic, Demonstrates Profound And Durable Reductions In Ldl-cholesterol, Apolipoprotein B, And ANGPTL3 In Patients With HoFH; Gateway Final Results

Frederick Raal

May 7, 2025 | HoFH Awareness Day, FH Week, Late Breaker Session: Clinical

Atherosclerosis phenotyping using artificial intelligence: implications for imaging

Ron Blankstein

May 7, 2025 | Plenary 03

Gain unprecedented insights into CVD with the latest -omics technologies using generative AI

Manuel Mayr

May 7, 2025 | Plenary 03

UK Biobank: scale, depth, duration…but, most importantly, accessibility

Rory Collins

May 7, 2025 | Plenary 03

Will AI cure Atherosclerotic Cardiovascular disease

Thomas Luscher

May 7, 2025 | Plenary 03

Advanced coronary CT in risk stratification

Edward Nicol

May 7, 2025 | Workshop: Assessing the vulnerable patient using non-invasive imaging

Can CT Coronary Angiography Impact On Lifestyle Behaviours And Preventative Therapy For Myocardial Infarction?

Phyo Khaing

May 7, 2025 | Workshop: Assessing the vulnerable patient using non-invasive imaging

Coronary Plaque Burden Assessed By Coronary CT Angiography In Individuals With Type 1 Diabetes And Good Glycemic Control Is Similar To Healthy Controls

Cheyenne Beverloo

May 7, 2025 | Workshop: Assessing the vulnerable patient using non-invasive imaging

Pericoronary Fat Attenuation Index (FAI) As A Predictive Biomarker For Major Adverse Cardiovascular Events (MACE) And Coronary Plaque Instability: Insight From A Meta-analysis Study

Muhammad Adda'i

May 7, 2025 | Workshop: Assessing the vulnerable patient using non-invasive imaging

The role of imaging in finding the high-risk patient

Jonathan Weir-McCall

May 7, 2025 | Workshop: Assessing the vulnerable patient using non-invasive imaging

Validation and Genetic Insights of Subclinical Carotid Atherosclerosis Endotypes in the UK Biobank

Qiaosen Chen

May 7, 2025 | Workshop: Assessing the vulnerable patient using non-invasive imaging

Detection Of Multicellular Transcriptional Programs And Immune Cell Phenotypes That Predict Outcomes Of Patients With Coronary Artery Disease

Timoteo Marchini

May 7, 2025 | Workshop: Inflammatory mechanisms in atherosclerosis

Endothelial Micronuclei Signatures And cGAS Activation: Key Determinants Of Atherosclerosis

Lucia Natarelli

May 7, 2025 | Workshop: Inflammatory mechanisms in atherosclerosis

IL-21 Receptor Deficiency Reduces Experimental Atherosclerosis By Modulating Immune Cells Responses

Danila Gurgone

May 7, 2025 | Workshop: Inflammatory mechanisms in atherosclerosis

Immune mediated diseases

Keith Channon

May 7, 2025 | Workshop: Inflammatory mechanisms in atherosclerosis

Infection: Immune Mechanisms of Cardivascular Disease in HIV

Annet Kirabo

May 7, 2025 | Workshop: Inflammatory mechanisms in atherosclerosis

Leveraging Genetic Risk Variants At HDAC9 To Identify Atherosclerotic Disease Mechanisms

Yaw Asare

May 7, 2025 | Workshop: Inflammatory mechanisms in atherosclerosis

Macrophage-secreted DNAse Prevents Neutrophil Extracellular Trap Mediated Impairment Of Efferocytosis In Atherosclerosis

Manikandan Subramanian

May 7, 2025 | Workshop: Inflammatory mechanisms in atherosclerosis

21st-century cardiovascular risk factors: heat and noise

Martin Röösli

May 7, 2025 | Workshop: New risk factors for atherosclerotic disease

Diagnostic Challenges In Familial Chylomicronemia Syndrome: The Relevance Of Lipoprotein Lipase Activity Beyond Scoring Systems

Gabriela Berg

May 7, 2025 | Rare Disease Day, Workshop: New risk factors for atherosclerotic disease

Micro- and Nanoplastics in Atheromas and Cardiovascular Events

Giuseppe Paolisso

May 7, 2025 | Workshop: New risk factors for atherosclerotic disease

Risk Reduction Of ASCVD Attributed To Lowering Of Remnant Cholesterol From Statins, Fibrates, APOC3 Inhibitors, And ANGPTL3 Inhibitors: A Cohort Study

Mie Balling

May 7, 2025 | Workshop: New risk factors for atherosclerotic disease

Safety And Efficacy Of Cholesteryl Ester Transfer Protein Inhibition: From Genetics To Outcome Trials

Brian Ference

May 7, 2025 | Workshop: New risk factors for atherosclerotic disease

Small For Gestational Age And Lipid Parameters During The First 14-16 Months Of Life

Sofie Taageby Nielsen

May 7, 2025 | Workshop: New risk factors for atherosclerotic disease

Stratification Of Future Atherosclerotic Cardiovascular Events’ Risks In The Primary Prevention Settings Of Japanese Heterozygous Familial Hypercholesterolemia: HeFH Risk Score Integrating Circulating Lipoprotein (a) Level

Sakaya Funabashi

May 7, 2025 | FH Week, Workshop: New risk factors for atherosclerotic disease

Modulators of inflammation in ASCVD

Christoph Binder

May 6, 2025 | ESC/EAS joint symposium

New Immune Players in Atherosclerosis – Implications for Diagnosis and Therapy

Claudia Monaco

May 6, 2025 | ESC/EAS joint symposium

Residual Cardiovascular Risk

Alberto Zambon

May 6, 2025 | ESC/EAS joint symposium

Role of incretins in control of vascular disease and function

Elena Osto

May 6, 2025 | ESC/EAS joint symposium

Hugh Sinclair Lecture: Stem Cells, Genomics, and AI for Drug Discovery

Joseph C. Wu

May 6, 2025 | 93rd EAS Congress 2025

Family planning in FH: practical guidance

Kirsten Holven

May 6, 2025 | FH Week, IAS/EAS Joint session: FH – Current status worldwide and how can implementation science help us improve

FH and implementation science (including IAS FH Guidance document)

Gerald Watts

May 6, 2025 | FH Week, IAS/EAS Joint session: FH – Current status worldwide and how can implementation science help us improve

Update from FHSC

Amany Elshorbagy

May 6, 2025 | FH Week, IAS/EAS Joint session: FH – Current status worldwide and how can implementation science help us improve

Update from HICC registry

Marina Cuchel

May 6, 2025 | FH Week, IAS/EAS Joint session: FH – Current status worldwide and how can implementation science help us improve

Beyond Guidelines – Integrating Emerging Evidence

Francisco Araujo

May 6, 2025 | Industry Sponsored Special Lecture

Attacking Scylla or Charybdis: Cholesterol or weight reduction for reduction of atherosclerotic CVD?

Naveed Sattar

May 6, 2025 | Plenary 02

Environmental pollution: a modifiable risk factor?

Naveed Sattar

May 6, 2025 | Plenary 02

Per particle importance of remnants vs. Lp(a) vs. LDL on cardiovascular disease risk

Elias Björnson

May 6, 2025 | Lp(a) Awareness Day, 93rd EAS Congress 2025, Plenary 02

Targeting adaptive immunity in atherosclerotic cardiovascular disease

Ziad Mallat

May 6, 2025 | Plenary 02

Acute Myocardial Infarction Care in Korea

Soon Jun Hong

May 6, 2025 | Special EAS session: Global Highlights

India – ASCVD and lipid management in India

J. P. S. Sawhney

May 6, 2025 | Special EAS session: Global Highlights

LatAm

Pablo Corral

May 6, 2025 | Special EAS session: Global Highlights

LIPRA

Ashraf Reda

May 6, 2025 | Special EAS session: Global Highlights

AAV Gene Therapy For Homozygous Familial Hypercholesterolemia: Translational Studies And Early Phase I Trial Interim Results

Chenbo Xu

May 6, 2025 | FH Week, Workshop: Optimisation of clinical management with novel or established treatments

Adherence To Lipid Lowering Medication In Genetic Familial Hypercholesterolemia And Cardiovascular Risk: A Registry Cohort Study

Ingrid Engebretsen

May 6, 2025 | FH Week, Workshop: Optimisation of clinical management with novel or established treatments

Bempedoic Acid And Limb Outcomes In Statin-intolerant Patients With Peripheral Artery Disease

Mario Enrico Canonico

May 6, 2025 | Workshop: Optimisation of clinical management with novel or established treatments

Functional Characterization Of Variants Of Uncertain Significance (VUS) In Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Using A Flow Cytometry Assay

Stella Covino

May 6, 2025 | FH Week, Workshop: Optimisation of clinical management with novel or established treatments

Integrating multidisciplinary data for advance pheno mapping of risk factors

Evangelos Oikonomou

May 6, 2025 | Workshop: Optimisation of clinical management with novel or established treatments

Lomitapide In Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) – Analysis Of Long-term (104-week) Safety And Efficacy From The Aph-19 Study

Luis Masana

May 6, 2025 | HoFH Awareness Day, FH Week, Workshop: Optimisation of clinical management with novel or established treatments

Using advanced phenotyping tools to enrich clinical trials: Is it time for companion diagnostics?

Jan Nilsson

May 6, 2025 | Workshop: Optimisation of clinical management with novel or established treatments

Geospatial Clustering Of Autoantibodies Against Apolipoprotein A-1 And Environmental Pollution In The Geneva General Population

Noé Fellay

May 6, 2025 | Workshop: e-Health AI and big data

Impact Of The Transition To Score 2; Gap In The Assessment Of Low-risk Patients And Assessment Of Statin Eligibility For All Risk Categories

Deniz Demirci

May 6, 2025 | Workshop: e-Health AI and big data

Predicting Long-term Cardiovascular Risk Using Machine Learning: 20-year Data From The Attica Study

Fotios Barkas

May 6, 2025 | Workshop: e-Health AI and big data

Proteins Predicting Arterial Stiffness And High Blood Pressure And Their Association With Cardiovascular Outcomes: Results From UK Biobank

Matteo Lemoli

May 6, 2025 | Workshop: e-Health AI and big data

AI and digitization in clinical practice

Calum Macrae

May 6, 2025 | Workshop: e-Health AI and big data

Using smart devices to monitor cardiovascular health

Rohan Khera

May 6, 2025 | Workshop: e-Health AI and big data

Apo-CIII Proteoforms Are Associated With Better Lipid, Inflammatory, And Glucose Profiles

Pere Rehues

May 6, 2025 |

Beyond reverse cholesterol: is HDL biologically relevant for what?

Laura Calabresi

May 6, 2025 | Workshop: HDL and other lipoproteins

Cerebrospinal Fluid And Plasma HDL (Dys)function In Multiple Sclerosis

Marcella Palumbo

May 6, 2025 | Workshop: HDL and other lipoproteins

Competitive Displacement Of Lipoprotein Lipase From Heparan Sulfate Is Orchestrated By A Disordered Acidic Cluster In GPIHBP1

Anamika Biswas

May 6, 2025 | Workshop: HDL and other lipoproteins

LDL And Non-HDL Cholesterol With The Lowest Mortality In The General Population In 1991-2018

Takahito Doi

May 6, 2025 | Workshop: HDL and other lipoproteins

Long-term Metabolic Effect Of The E97G Gain-of-function Variant Of Hepatic Lipase In High-fat Diet Fed C57BL6/J Mice

Cedric Le May

May 6, 2025 | Workshop: HDL and other lipoproteins

Mitochondria As Novel Modulators Of Ldlr Plasmamembrane Availability: The Role Of Carmaboyl Phosphate Synthetase 1

Maria Giovanna Lupo

May 6, 2025 | Workshop: HDL and other lipoproteins

Therapeutic targeting of HDL: Should we keep trying?

John Chapman

May 6, 2025 | Workshop: HDL and other lipoproteins

ADAR2 Promotes Atherosclerosis In Mice And Humans

Simon Tual-Chalot

May 6, 2025 | Workshop: Identifying Novel Therapeutic Approaches in Atherosclerosis

Engineered Human CD34+ Hematopoetic Stem Cells As An Innovative Approach To Modulate The Immunoinflammatory Response During Atherosclerosis

Arianna Moretti

May 6, 2025 | Workshop: Identifying Novel Therapeutic Approaches in Atherosclerosis

Functional lipid profiling of human leukocytes to improve cardiovascular risk assessment

Simon Pfisterer

May 6, 2025 | Workshop: Identifying Novel Therapeutic Approaches in Atherosclerosis

Mitochondrial Oxidative Stress Drives Macrophage Plasticity In Atherosclerosis

Laura Boccuni

May 6, 2025 | Workshop: Identifying Novel Therapeutic Approaches in Atherosclerosis

Proteomic Characterisation Of Recently Identified Molecular Plaque Subtypes And Unravelling Lesion Diversity In Atherosclerosis

Kaylin Palm

May 6, 2025 | Workshop: Identifying Novel Therapeutic Approaches in Atherosclerosis

The role of innate immune reprogramming in the pathophysiology of atherosclerosis – a targetable approach?

Niels Riksen

May 6, 2025 | Workshop: Identifying Novel Therapeutic Approaches in Atherosclerosis

Antigen specific T-cell interactions in the atherosclerotic lesion

Bram Slütter

May 6, 2025 | Workshop: Intercellular communication and atherosclerotic plaque phenotype

Elucidating The Molecular Mechanisms Of Human Smooth Muscle Cell Plasticity: A Translational In Vitro Platform For Therapeutic Target Discovery In Coronary Artery Disease

Liliana Som

May 6, 2025 | Workshop: Intercellular communication and atherosclerotic plaque phenotype

Histomorphology-guided Integrative Proteomics Reveals Subregion-specific Extracellular Protein Signatures Of Vulnerable Carotid Plaques

Ankit Sinha

May 6, 2025 | Workshop: Intercellular communication and atherosclerotic plaque phenotype

Non-canonical WNT Signalling Promotes Vascular Smooth Muscle Cell Calcification via Complement 3

Ileana Badi

May 6, 2025 | Workshop: Intercellular communication and atherosclerotic plaque phenotype

PRDM16 Controls Plaque Composition By Modulating Smooth Muscle Cell Identity

Josephine M. E. Tan

May 6, 2025 | Workshop: Intercellular communication and atherosclerotic plaque phenotype

The FAT1 Cadherin Restricts Smooth Muscle Cell Metabolic Reprogramming And Limits Atherosclerotic Lesion Expansion

Dario Riascos-Bernal

May 6, 2025 | Workshop: Intercellular communication and atherosclerotic plaque phenotype

Using multi-omics to decipher plaque destabilisation processes

Lars Maegdefessel

May 6, 2025 | Workshop: Intercellular communication and atherosclerotic plaque phenotype

Association Of Lipoprotein(a) With Coronary Atherosclerotic Plaque Characteristics Detected By Three-vessel Optical Coherence Tomography In Patients With Acute Myocardial Infarction

Chao Fang

May 6, 2025 | Workshop: Lp(a) – Joint session with British Pharmacological Society

Lipoprotein (a) And Incident Coronary Heart Disease In The Community: Impact Of Traditional Cardiovascular Risk Factors

Natalie Arnold

May 6, 2025 | Workshop: Lp(a) – Joint session with British Pharmacological Society

Lipoprotein(a) And Risk Of Dementia: Three Independent Cohort Studies Including 575,630 Individuals

Peter Thomas

May 6, 2025 | Workshop: Lp(a) – Joint session with British Pharmacological Society

Lipoprotein(a) Is An Apoe-containing Particle Enriched In Triglyceride Species Associated With Incident Cardiovascular Disease

Kaloyan Takov

May 6, 2025 | Workshop: Lp(a) – Joint session with British Pharmacological Society

Lipoprotein(a) Values In Children With Hypercholesterolemia

Matej Mlinarič

May 6, 2025 | Workshop: Lp(a) – Joint session with British Pharmacological Society

Lp(a) the new target

Sotirios Tsimikas

May 6, 2025 | Lp(a) Awareness Day, 93rd EAS Congress 2025, Workshop: Lp(a) – Joint session with British Pharmacological Society

Should we do cascade screening for Lp(a)?

Jaimini Cegla

May 6, 2025 | Lp(a) Awareness Day, 93rd EAS Congress 2025, Workshop: Lp(a) – Joint session with British Pharmacological Society

Cholesterol-lowering Drug Targets Reduce Risk Of Vascular-related Dementia: Mendelian Randomization Of 500,000 Individuals

Liv Nordestgaard

May 6, 2025 | Workshop: Young fellows session: The cardiovascular – brain axis

Endothelial Deletion Of The Glycolytic Regulator PFKFB3 Exacerbates Vascular Inflammation And Atherosclerosis In Mice

Xiaohan Zhang

May 6, 2025 | Workshop: Young fellows session: The cardiovascular – brain axis

Neural control of cardiovascular inflammation

Peder Olofsson

May 6, 2025 | Workshop: Young fellows session: The cardiovascular – brain axis

Sleep and cardiovascular risk

Cameron McAlpine

May 6, 2025 | Workshop: Young fellows session: The cardiovascular – brain axis

The Alzheimer’s Disease Related Protein, BACE1, Is A Novel Drug Target For Atherosclerosis Development

Paul Meakin

May 6, 2025 | Workshop: Young fellows session: The cardiovascular – brain axis

The Calcium-sensing Receptor (CaSR) Plays A Cell-specific Multifaceted Role In Atherosclerosis

Sanne Maas

May 6, 2025 | Workshop: Young fellows session: The cardiovascular – brain axis

Transient Expression Of Reg3β By Smooth Muscle Cells Affects Atherosclerosis In Mice

Laia Cañes Esteve

May 6, 2025 | Workshop: Young fellows session: The cardiovascular – brain axis

Hypertriglyceridemia and Atherosclerosis: Beyond LDL-C

Michael David Shapiro

May 5, 2025 | ASPC-EAS Joint session, 93rd EAS Congress 2025

Novel Approaches to Lowering Triglycerides: Current and Future Therapies

Arca Marcello

May 5, 2025 | ASPC-EAS Joint session, 93rd EAS Congress 2025

The Genetics of Hypertriglyceridemia: Insights into Pathophysiology and Risk

Anne Tybjaerg-Hansen

May 5, 2025 | ASPC-EAS Joint session, 93rd EAS Congress 2025

Triglycerides, Remnant Cholesterol, and ASCVD Risk: Practical Guidance for Clinicians

Martha Gulati

May 5, 2025 | ASPC-EAS Joint session, 93rd EAS Congress 2025

Early and effective: Combination Therapy for Optimal LDL-C Reduction (SWEDEHEART, CLEAR Outcomes)

Julia Brandts

May 5, 2025 | CME Session: Combination Therapy for LDL-C

Implementation gaps: Data from Real world evidence in Europe

Kausik Ray

May 5, 2025 | ASPC-EAS Joint session, 93rd EAS Congress 2025

Is it time for triple combination therapy?

Alberto Zambon

May 5, 2025 | CME Session: Combination Therapy for LDL-C, 93rd EAS Congress 2025

Lp(a) in the Real World: Cases of primary and secondary prevention

Leslie Cho

May 5, 2025 | Lp(a) Awareness Day, CME Session: High Lp(a): why does it matter?, 93rd EAS Congress 2025

Clinical consequences of high Lp(a)

Pia R. Kamstrup

May 5, 2025 | Lp(a) Awareness Day, CME Session: High Lp(a): why does it matter?, 93rd EAS Congress 2025

My patient has high Lp(a). What do I do?

Erik Stroes

May 5, 2025 | Lp(a) Awareness Day, CME Session: High Lp(a): why does it matter?, 93rd EAS Congress 2025

Why is Lp(a) a causal risk factor for ASCVD?

Ulf Landmesser

May 5, 2025 | Lp(a) Awareness Day, CME Session: High Lp(a): why does it matter?, 93rd EAS Congress 2025

Is LDL lowering a solved problem?

Børge Nordestgaard,

Kausik Ray

May 5, 2025 | 93rd EAS Congress 2025

Clinical experience with evinacumab at Evelina London Children’s Hospital

Mike Champion

May 5, 2025 | FH Week, Industry Sponsored Educational Symposium

Efficacy and safety of evinacumab in patients with HoFH: A review of the clinical data in adult, adolescent and paediatric patients

Frederick Raal

May 5, 2025 | HoFH Awareness Day, FH Week, Industry Sponsored Educational Symposium

Homozygous familial hypercholesterolaemia (HoFH): Aetiology, presentation and diagnosis through the lens of the HICC registry – Where are the ‘missing’ patients?

Marina Cuchel

May 5, 2025 | HoFH Awareness Day, FH Week, Industry Sponsored Educational Symposium

Welcome and introduction

Jaimini Cegla

May 5, 2025 | FH Week, Industry Sponsored Educational Symposium

Cardiovascular benefits of icosapent ethyl* in REDUCE-IT

Kausik Ray

May 5, 2025 | Industry Sponsored Special Lecture

EPA’s Mechanism of Action: Connecting the Dots

Alberto Zambon

May 5, 2025 | Industry Sponsored Special Lecture

Doxorubicin Promotes Atherosclerosis In An Apolipoprotein E-deficient Mouse Model, Potentially Associated With Serpina3n

Sander Eens

May 5, 2025 | Late Breaker Session: Basic & Translational Late Breaking Science

Examining The Effects Of Rituximab On The B Cell Receptor Repertoire in Acute Myocardial Infarction

James O'Brien

May 5, 2025 | Late Breaker Session: Basic & Translational Late Breaking Science

Inclisiran As Monotherapy Compared With Placebo Or Ezetimibe In Patients At Low To Borderline Atherosclerotic Cardiovascular Disease Risk: Results From The Victorion-mono Randomized Clinical Trial

Pam Taub

May 5, 2025 | Late Breaker Session: Basic & Translational Late Breaking Science

Oscillatory Shear Stress Regulates Stress Granule Dynamics And Its Interaction With Ppard During Atherogenesis

Xiao-Yu Tian

May 5, 2025 | Late Breaker Session: Basic & Translational Late Breaking Science

Potent, Durable, And Safe LDL-C Reduction In Non-human Primates With A Novel Crispr-based Epigenetic Silencer At Therapeutically Relevant Doses

Aarif Khakoo

May 5, 2025 | Late Breaker Session: Basic & Translational Late Breaking Science

Spatial Proteomics Of The Human Atherosclerotic Microenvironment Reveals Heterogeneity In Intra-plaque Proteomes And Extracellular Matrix Remodeling

Luke Gamon

May 5, 2025 | Late Breaker Session: Basic & Translational Late Breaking Science

LDL-C Reduction

Kausik Ray

May 5, 2025 | NLA/EAS joint session

Lp(a) Management

Christie Ballantyne

May 5, 2025 | Lp(a) Awareness Day, 93rd EAS Congress 2025, NLA/EAS joint session

Remnant Cholesterol and Triglyceride-Rich Lipoproteins

Børge Nordestgaard

May 5, 2025 | NLA/EAS joint session

Systems Approaches to Improving Lipid Management

Kaye-Eileen Willard

May 5, 2025 | NLA/EAS joint session

Acute Coronary Syndromes in the absence of standard modifiable risk factors (SMURFs): Is sex the missing link?

Gemma Figtree

May 5, 2025 | Plenary 01

Deciphering the code: Exploring the influence of biological sex and cardiometabolic disease development

Karen Reue

May 5, 2025 | Plenary 01

Gender medicine: Effects of sex and gender on cardiovascular disease manifestation and outcomes

Vera Regitz-Zagrosek

May 5, 2025 | Plenary 01

Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women

Lale Tokgözoğlu

May 5, 2025 | Plenary 01

Current Guidelines Result In Extensive Pregnancy-related Off-treatment Time In Women With Familial Hypercholesterolemia

Marianne Klevmoen

May 5, 2025 | FH Week, Workshop: (DE) Implementing new tools in clinical practice

Proteomic Signatures as Biomarkers of Atherosclerosis

Lanyue Zhang

May 5, 2025 | Workshop: (DE) Implementing new tools in clinical practice

Digital health solutions for personalised prevention

John Deanfield

May 5, 2025 | Workshop: (DE) Implementing new tools in clinical practice

High-intensity Statin Vs Initial Combination Of Statin And Ezetimibe Following A First Coronary Event: A Nationwide Population-based Cohort Study

Bertrand Cariou

May 5, 2025 | Workshop: (DE) Implementing new tools in clinical practice

Novel Ai Technology To Quantify Coronary Inflammation And Cardiovascular Risk With Routine Coronary Computed Tomography Angiography: A Cost-effectiveness Analysis

Kenneth Chan

May 5, 2025 | Workshop: (DE) Implementing new tools in clinical practice

The #LILAC-for-Lp(a) Approach Disseminated Via A Short-educational Video Improves Confidence And Perception Of Healthcare Professionals – A Pilot Implementation Study

Wann Jia Loh

May 5, 2025 | Workshop: (DE) Implementing new tools in clinical practice

When should cardiovascular medicines be discontinued?

Konstatin Krychtiuk

May 5, 2025 | Workshop: (DE) Implementing new tools in clinical practice

A Loss-of-function Missense Variant In ANGPTL3 Exerts Protective Effects Against Kidney Disease Risk

David Zhang

May 5, 2025 | Workshop: Atherosclerosis as a multi-organ disease

Atherosclerosis, hypertension and the kidney

Maciej Tomaszewski

May 5, 2025 | Workshop: Atherosclerosis as a multi-organ disease

Cardiometabolic effects of SGLT2 inhibition

Paola Fioretto

May 5, 2025 | Workshop: Atherosclerosis as a multi-organ disease

Impact Of Metabolic Status On Mortality Across Steatotic Liver Disease Subtypes: Insights From a US Cohort Study

Guyu Zeng

May 5, 2025 | Workshop: Atherosclerosis as a multi-organ disease

Metabolic Syndrome And Risk Of Vascular-related Dementia In High-risk And Low-risk Prospective Cohorts

Ida Juul Rasmussen

May 5, 2025 | Workshop: Atherosclerosis as a multi-organ disease

Subphenotyping Approach In Persons With Elevated Risk Of Diabetes Identifies Individuals With Increased Arterial Stiffness, Irrespective Of Classical Glucose Tolerance Classification

Maurizio Di Marco

May 5, 2025 | Workshop: Atherosclerosis as a multi-organ disease

Unraveling The Vascular Threat: Elevated Risk And Poor Prognosis Of Aortic Aneurysms And Dissections In Polycystic Kidney Disease

Pao-Hsien Chu

May 5, 2025 | Workshop: Atherosclerosis as a multi-organ disease

Emerging Computer Vision Approaches to Assess Social and Environmental Risk for Cardiometabolic Disease

Sanjay Rajagopalan

May 5, 2025 | Workshop: Beyond conventional cardiovascular risk

Cardiovascular-immunometabolic Profile In Survivors Of Acute Lymphoblastic Leukaemia (SALL)

Fabrizia Bonacina

May 5, 2025 | Workshop: Beyond conventional cardiovascular risk

Ethnicity as a risk factor: How “modifiable” is it?

Ilonca Vaartjes

May 5, 2025 | Workshop: Beyond conventional cardiovascular risk

Females Exhibit Greater Mitochondrial Endothelial Dysfunction, Impairing Vascular Healing In Diabetes-associated Peripheral Artery Disease

Sian Cartland

May 5, 2025 | Workshop: Beyond conventional cardiovascular risk

Smooth Muscle Cell Specific Mitochondrial Dysfunction Exacerbates Abdomnial Aortic Aneurysm in Mice

Goo Taeg Oh

May 5, 2025 | Workshop: Beyond conventional cardiovascular risk

Role Of The Lysine Methyltransferase SET7 In Obesity-related Endothelial Dysfunction: Novel Molecular Targets

Julia Sánchez-Ceinos

May 5, 2025 | Workshop: Beyond conventional cardiovascular risk

The Aryl Hydrocarbon Receptor As Novel Regulator Of Atherosclerosis

Rosanna Huchzermeier

May 5, 2025 | Workshop: Beyond conventional cardiovascular risk

A Novel Epigenetic Editor Targeting PCSK9 Achieves Maximal Pharmacological Effect With An Increased Therapeutic Window In Non-human Primates

John Xiong

May 5, 2025 | Workshop: New targets for therapy

Cholesterol-lowering ISMA-encoding Gut Bacteria Mitigate Atherosclerosis

Seyed Soheil Saeedi Saravi

May 5, 2025 | Workshop: New targets for therapy

Nonclinical Data Demonstrate Potent And Precise Inactivation Of Liver Pcsk9 In Vivo With The Clinical Stage GalNAc Base Editing Medicine, VERVE-102

Scott Vafai

May 5, 2025 | Workshop: New targets for therapy

Pharmacological Induction Of Mitochondrial Uncoupling By BAM15 Attenuates Atherosclerosis Development In APOE*3-Leiden.CETP Mice

Jamie Van Der Vaart

May 5, 2025 | Workshop: New targets for therapy

Redefining Steatotic Liver Disease to identify novel targets to treat cardiovascular disease

Stefano Romeo

May 5, 2025 | Workshop: New targets for therapy

The crosstalk between lipid metabolism, energetic demand and thyroid hormones: pharmacological opportunities

Giuseppe Danilo Norata

May 5, 2025 | Workshop: New targets for therapy

How to win the Nobel Prize?

Göran K. Hansson

May 4, 2025 | 93rd EAS Congress 2025

The Anitschkow Lecture 2025: Beyond LDL: inflammation screening and inflammation inhibition for atherosclerotic disease

Paul Ridker

May 4, 2025 | 93rd EAS Congress 2025

How to identify the very high CV risk patients

Francois Mach

May 4, 2025 | CME Session: Intensive and Early Ldl-C Treatment: for Whom?

Novel approach to improve patients’ outcome

Pasquale Perrone Filardi

May 4, 2025 | CME Session: Intensive and Early Ldl-C Treatment: for Whom?

Very high cardiovascular patients risk profiles across the ASCVD continuum

Ulrich Laufs

May 4, 2025 | CME Session: Intensive and Early Ldl-C Treatment: for Whom?

Getting to the sweet spot: too much or too little

Kausik Ray

May 4, 2025 | CME Session: Pre/Event Management of LDL-C

Identifying and managing the Pre-Event patient

Lale Tokgözoğlu

May 4, 2025 | CME Session: Pre/Event Management of LDL-C

What is new on the horizon?

Nicholas Marston

May 4, 2025 | CME Session: Pre/Event Management of LDL-C

Evaluating the return of additional findings from the 100,000 Genomes Project: A mixed methods study exploring participant experiences of receiving secondary findings from genomic sequencing.

Bethany Stafford-Smith,

Morgan Daniel,

Michelle Peter,

Jana Gurasashvili,

Rashida Baptiste,

Xavier Bracke-Manzanares,

Lamprini Georgiou,

Adele Green-Armytage,

Blanche Griffin,

Bethany Lumborg,

Ben Paternoster,

Emma Smith,

Meena Balasubramanian,

Lucy Bownass,

Paul Brennan,

Ruth Cleaver,

Virginia Clowes,

Philandra Costello,

Bianca DeSouza,

Louise Dubois,

Angela George,

Elaine George,

Rachel Harrison,

Lara Hawkes,

Steve Humphries,

Alan Jones,

Elizabeth A Jones,

Alison Kraus,

Deborah Holiday,

Meriel McEntagart,

Suresh Somarathi,

Amy Taylor,

Vishakha Tripathi,

Stephen Morris,

Lyn S Chitty,

Melissa Hill

April 19, 2025 | Psychological impact of FH diagnosis, Publication, Paediatric Lipid Working Group

Genetic Determinants of the Familial Hypercholesterolaemia Phenotype.

Steve Humphries,

Marta Futema

April 2, 2025 | Genetics of FH, Publication, Paediatric Lipid Working Group

Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): A retrospective cohort study of individuals with FH in UK primary care and the UK Simon Broome register, linked with national hospital records.

Barbara Iyen,

Nadeem Qureshi,

Joe Kai,

N. Capps,

P N Durrington,

Jaimini Cegla,

Handrean Soran,

J Schofield,

H A W Neil,

Steve Humphries

April 1, 2025 | Clinical studies of atherosclerosis in FH, Publication, Paediatric Lipid Working Group

Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry.

Amany Elshorbagy,

Antonio J. Vallejo-Vaz,

Fotios Barkas,

Alexander R M Lyons,

Christophe A T Stevens,

Kanika I Dharmayat,

Alberico L. Catapano,

Tomas Freiberger,

Kees Hovingh,

Pedro Mata,

Frederick Raal,

Raul Santos,

Handrean Soran,

Gerald Watts,

Marianne Abifadel,

Carlos A Aguilar-Salinas,

Khalid F Alhabib,

Mutaz Al-Khnifsawi,

Wael Almahmeed,

Fahad Alnouri,

Rodrigo Alonso Alonso,

Khalid Al-Rasadi,

Ahmad Al-Sarraf,

Arca Marcello,

Tester F Ashavaid,

Maurizio Averna,

Maciej Banach,

Marianne Becker,

Christoph Binder,

Mafalda Bourbon,

Liam Brunham,

Krzysztof Chlebus,

Pablo Corral,

Diogo Cruz,

Kairat Davletov,

Olivier S Descamps,

Bambang Dwiputra,

Marat Ezhov,

Urh Groselj,

Mariko Harada-Shiba,

Kirsten Holven,

Steve Humphries,

Meral Kayikcioglu,

Weerapan Khovidhunkit,

Katarina Lalic,

Gustavs Latkovskis,

Ulrich Laufs,

Evangelos Liberopoulos,

Marcos M Lima-Martinez,

Vincent Maher,

David Marais,

Winfried März,

Erkin Mirrakhimov,

André R Miserez,

Olena Mitchenko,

Hapizah Nawawi,

Børge Nordestgaard,

Andrie G Panayiotou,

György Paragh,

Zaneta Petrulioniene,

Belma Pojskic,

Arman Postadzhiyan,

Ashraf Reda,

Zeljko Reiner,

Ximena Reyes,

Fouzia Sadiq,

Wilson Ehidiamen Sadoh,

Heribert Schunkert,

Aleksandr Shek,

Erik Stroes,

Ta-Chen Su,

Tavintharan Subramaniam,

Andrey V Susekov,

Myra Tilney,

Brian Tomlinson,

Thanh Huong Truong,

Alexandros Tselepis,

Anne Tybjaerg-Hansen,

Alejandra Vázquez-Cárdenas,

Margus Viigimaa,

Branislav Vohnout,

Shizuya Yamashita,

Kausik Ray

March 24, 2025 | Epidemiology of FH, Publication, Paediatric Lipid Working Group

Cardiovascular challenges in androgen therapies: From androgen deficiency to gender dysphoria

Fabrice Bonnet,

Åsa Tivesten

March 20, 2025 | Webinars on-demand

Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials.

Alexis Llewellyn,

Mark Simmonds,

David Marshall,

Melissa Harden,

Steve Humphries,

Uma Ramaswami,

Lorraine Priestley-Barnham,

Mark Fisher,

Laila J Tata,

Nadeem Qureshi

February 1, 2025 | Treatment of FH, Publication, Paediatric Lipid Working Group

Effectiveness of lipid lowering therapies around the world

Kausik Ray

December 11, 2024 | Webinars on-demand, EAS-LatAm webinar series

Actions to improve the quality of care for patients with dyslipidemia: the case for Europe

Alexandros Tselepis

December 11, 2024 | Webinars on-demand, EAS-LatAm webinar series

Actions to improve the quality of care for patients with dyslipidemia: the case for Latin America

Andrei Sposito

December 11, 2024 | Webinars on-demand, EAS-LatAm webinar series

Patients with high and very high CV risk: which are treatment options?

Ulrich Laufs

December 5, 2024 | LCN Webinars, Lipid Clinic Network

Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families?

Uma Ramaswami,

Lorraine Priestley-Barnham,

Steve Humphries

December 1, 2024 | Screening for FH, Publication, Paediatric Lipid Working Group

CV risk in primary prevention: how to detect high and very high risk patients

Alberico L. Catapano

November 15, 2024 | LCN Webinars, Lipid Clinic Network

Gene-based therapies for atherosclerosis treatment

Maciej Banach,

Sotirios Tsimikas,

Charalambos Antoniades,

Alexandros Tselepis

November 13, 2024 | Webinars on-demand

Variants in LPA are associated with Familial Hypercholesterolaemia: whole genome sequencing analysis in the 100,000 Genomes Project.

Martin Bird,

Antoine Rimbert,

Alan M Pittman,

Steve Humphries,

Marta Futema

November 12, 2024 | Genetics of FH, Publication, Paediatric Lipid Working Group

RLD 2024 Prague – Lp(a) elevation and its associated CVD risk

Jan Pit'ha

November 5, 2024 | EAS RLD 2024 Prague

RLD 2024 Prague – Rare dyslipidemias and their role in clinical practice

Jan Pit'ha

November 5, 2024 | EAS RLD 2024 Prague

RLD 2024 Prague – Rare causes of LDL-C elevation sitosterolemia, LAL-deficiency and beyond

Klaus Parhofer

November 5, 2024 | EAS RLD 2024 Prague

RLD 2024 Prague – Familial dysbetalipoproteinemia: Do we understand its pathophysiology?

Michal Vrablik

November 5, 2024 | EAS RLD 2024 Prague

RLD 2024 Prague – Update on homozygous FH: genotype and phenotype correlations

Tomas Freiberger

November 5, 2024 | EAS RLD 2024 Prague

RLD 2024 Prague – Patient with extremely low total/LDL cholesterol (Hypo- and abetalipoproteinemia and beyond)

Vladimiír Blaha

November 5, 2024 | EAS RLD 2024 Prague

Newborn screening for lipid disorders

Xiangqiang Shao,

Robert D Steiner,

Amy L Peterson

November 3, 2024 | Other, Paediatric Lipid Working Group

RLD 2024 Greece – 01 – Welcome

Evangelos Liberopoulos,

Haralampos Milionis

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 02 – Overview of human lipid metabolism

Alexandros Tselepis

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 03 – Q&A – Overview of human lipid metabolism

Alexandros Tselepis

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 04 – Homozygous familial hypercholesterolemia

Evangelos Liberopoulos

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 05 – Q&A – Homozygous familial hypercholesterolemia

Evangelos Liberopoulos

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 06 – Extreme high lipoprotein(a) levels

Niki Katsiki

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 07 – Q&A – Extreme high lipoprotein(a) levels

Niki Katsiki

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 08 – Sitosterolemia

Theodosios Filippatos

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 09 – Q&A – Sitosterolemia

Theodosios Filippatos

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 10 – Dysbetalipoproteinemia

Jeanine Roeters van Lennep

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 11 – Q&A – Dysbetalipoproteinemia

Jeanine Roeters van Lennep

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 12 – Low HDL cholesterol disorders

Kyriakos Kypreos

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 13 – Q&A – Low HDL cholesterol disorders

Kyriakos Kypreos

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 14 – Lysosomal Acid Lipase Deficiencies

Haralampos Milionis

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 15 – Q&A – Lysosomal Acid Lipase Deficiencies

Haralampos Milionis

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 16 – Chylomicronemia syndrome

Stefano Romeo

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece 17 – Q&A – Chylomicronemia syndrome

Stefano Romeo

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 18 – Hypobetalipoprotenemia and abetalipoprotenemia

Fotios Barkas

September 27, 2024 | EAS RLD 2024 Athens

RLD 2024 Greece – 19 – Q&A – Hypobetalipoprotenemia and abetalipoprotenemia

Fotios Barkas

September 27, 2024 | EAS RLD 2024 Athens

Potential atherogenicity of tryglyceride-rich lipoproteins

Laura Schreier

September 5, 2024 | Webinars on-demand, EAS-LatAm webinar series

TG-rich lipoproteins: stars or second advantage in the field of residual CV risk?

Alberto Zambon

September 5, 2024 | Webinars on-demand, EAS-LatAm webinar series

Dyslipidemia and cardiovascular risk in LATAM

Isabel Cristina Cárdenas Moreno

June 26, 2024 | Webinars on-demand, EAS-LatAm webinar series

What are the therapeutic objectives of LDL, Non-HDL cholesterol, lipoprotein (a), and apolipoprotein B according to cardiovascular risk?

Dora Ines Molina de Salazar

June 26, 2024 | Webinars on-demand, EAS-LatAm webinar series

Barriers to achieving LDL cholesterol goals in LATAM

Dora Ines Molina de Salazar,

Isabel Cristina Cárdenas Moreno

June 26, 2024 | Webinars on-demand, EAS-LatAm webinar series

How Early is too Early for ASCVD Prevention?

John William McEvoy

May 29, 2024 | 92nd EAS Congress 2024, ASPC-EAS joint session

Women and Risk Factors for ASCVD: Sex Specific Considerations

Jeanine Roeters van Lennep

May 29, 2024 | 92nd EAS Congress 2024, ASPC-EAS joint session

Debate: Coronary Artery Calcification is Primary Prevention (Pro/Con)

Raul Santos,

Michael David Shapiro

May 29, 2024 | 92nd EAS Congress 2024, ASPC-EAS joint session

Global Primordial Prevention of Cardiovascular Diseases

Bamba Gaye

May 29, 2024 | 92nd EAS Congress 2024, Precision medicine and ASCVD

Consequences of Gender Transition on ASCVD risk: A clinical perspective

Åsa Tivesten

May 29, 2024 | 92nd EAS Congress 2024, Precision medicine and ASCVD

Compensatory metabolic responses in ChREBP-deficient brown adipose tissue

Ludger Scheja

May 29, 2024 | 92nd EAS Congress 2024, New insights in the regulation of Lipid/Lipoproteins metabolism

Lipid regulatory effects of endothelial force sensing

Laeticia Lichtenstein

May 29, 2024 | 92nd EAS Congress 2024, New insights in the regulation of Lipid/Lipoproteins metabolism

ANGPTL3 interacts and inhibits PCSK9 in an in vitro cellular model

Simone Bini

May 29, 2024 | 92nd EAS Congress 2024, New insights in the regulation of Lipid/Lipoproteins metabolism

LIPC-E97G gain-of-function variant protects mice from dyslipidemia and atherosclerosis, independently of the LDLR receptor

Thibaud Sotin

May 29, 2024 | 92nd EAS Congress 2024, New insights in the regulation of Lipid/Lipoproteins metabolism

Lipoprotein lipase: How can an unstable enzyme orchestrate intravascular lipolysis?

Michael Ploug

May 29, 2024 | 92nd EAS Congress 2024, New insights in the regulation of Lipid/Lipoproteins metabolism

The role of ANGPTL8 in the regulation of triglyceride metabolism

Robert Konrad

May 29, 2024 | 92nd EAS Congress 2024, New insights in the regulation of Lipid/Lipoproteins metabolism

Multi-omics in CV-medicine

Erik Stroes

May 29, 2024 | 92nd EAS Congress 2024, Plenary 03

Contribution of metabolomics and inflammation

Samia Mora

May 29, 2024 | 92nd EAS Congress 2024, Plenary 03

Contribution of imaging

Giovanna Liuzzo

May 29, 2024 | 92nd EAS Congress 2024, Plenary 03

Contribution of genetics

Pradeep Natarajan

May 29, 2024 | 92nd EAS Congress 2024, Plenary 03

MicroRNAs reducing plasma cholesterol in apoB-containing lipoproteins without causing hepatosteatosis

Mahmood Hussain

May 28, 2024 | 92nd EAS Congress 2024, Plenary 02

New insights in the genetics of dyslipidemia

Catherine Boileau

May 28, 2024 | Plenary 02

Recent developments in system biology to understand atherosclerosis

Johan Björkegren

May 28, 2024 | Plenary 02

Translational opportunities of single-cell biology in atherosclerosis

Claudia Monaco

May 28, 2024 | 92nd EAS Congress 2024, Plenary 02

A practical approach to effective smoking cessation

Giuseppe Biondi-Zoccai

May 28, 2024 | ESC-EAS joint session

Exercise in individuals with obesity and multiple comorbidities: What works

Martin Bahls

May 28, 2024 | ESC-EAS joint session

Applying risk scores in clinical practice; What scores for which patients?

Lisa Pennells

May 28, 2024 | ESC-EAS joint session, 92nd EAS Congress 2024

Risk modifiers & cardiovascular prevention?

Maryam Kavousi

May 28, 2024 | ESC-EAS joint session, 92nd EAS Congress 2024

Connecting gut hormones and lipid metabolism

Niina Matikainen

May 28, 2024 | New Therapeutics, 92nd EAS Congress 2024

Bariatric surgery and lipids

Geltrude Mingrone

May 28, 2024 | New Therapeutics, 92nd EAS Congress 2024

Efficacy of Evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study

Frederick Raal

May 28, 2024 | New Therapeutics, 92nd EAS Congress 2024

Lomitapide in paediatric patients with homozygous familial hypercholesterolaemia: Analysis of patient-level LDL-C reduction, fat soluble vitamins, lipoproteins and patient maturation from APH-19 study

Lluis Masana

May 28, 2024 | New Therapeutics, 92nd EAS Congress 2024

MUIR Study Results: Plozasiran, an investigational RNAi therapeutic, silences apolipoprotein C3, and reduces atherosclerosis associated lipoproteins in patients with mixed hyperlipidemia

Christie Ballantyne

May 28, 2024 | New Therapeutics, 92nd EAS Congress 2024

The synthetic bile acid derivative norudca impairs mitochondrial function and adaptive thermogenesis

Joerg Heeren

May 28, 2024 | New Therapeutics, 92nd EAS Congress 2024

A novel cardiovascular-kidney-metabolic syndrome mouse model with inducible HFrEF and atherosclerosis

José Inia

May 28, 2024 | Young fellows session, 92nd EAS Congress 2024

Artificial Intelligence for Biomarker Identification in CVD

Amit V. Khera

May 28, 2024 | Young fellows session, 92nd EAS Congress 2024

Clonal hematopoiesis dynamics and subclinical atheroscleorisis in healthy middle-aged individuals

Miriam Díez-Díez

May 28, 2024 | Young fellows session, 92nd EAS Congress 2024

LIGHT deficiency in Apoe-/- mice increases atheroma plaque by enhancing apoptosis

Gema Hurtado-Genovés

May 28, 2024 | Young fellows session, 92nd EAS Congress 2024

Neutrophils as non-classical risk factors for ASCVD

Ruth Frikke-Schmidt

May 28, 2024 | Young fellows session, 92nd EAS Congress 2024

Semaglutide dampens residual inflammation in individuals with type 2 diabetes: preliminary results from the DOTAFLAME study

Reindert Oostveen

May 28, 2024 | Young fellows session, 92nd EAS Congress 2024

SCORE2: how does it perform in high risk eastern countries?

Emanuele Di Angelantonio

May 28, 2024 | Assessment of cardiovascular risk and gene editing therapeutics, 92nd EAS Congress 2024

Development and validation of a novel 10-year residual risk score (RRS) in the UK Biobank and Massachusetts General Brigham populations for patients with established ASCVD

Olga Mineeva

May 28, 2024 | Assessment of cardiovascular risk and gene editing therapeutics, 92nd EAS Congress 2024

Association of multiple polygenic risk scores with myocardial infarction and atherosclerotic coronary artery lesions in a Canadian population

Hasanga Manik Purage

May 28, 2024 | Assessment of cardiovascular risk and gene editing therapeutics, 92nd EAS Congress 2024

An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves precise and durable liver editing in nonclinical studies

Amit V. Khera

May 28, 2024 | Assessment of cardiovascular risk and gene editing therapeutics, 92nd EAS Congress 2024

Beyond traditional risk factors in screening for ASCVD in primary prevention

Laurens F Rens Reeskamp

May 28, 2024 | Assessment of cardiovascular risk and gene editing therapeutics, 92nd EAS Congress 2024

Controversy: Are we ready to treat inflammation for ASCVD prevention?

Paul Ridker,

Ulrich Laufs

May 28, 2024 | 92nd EAS Congress 2024, Controversy: Are we ready to treat inflammation for ASCVD prevention?

International survey on secondary prevention of cardiovascular disease across six WHO regions

David A. Wood

May 28, 2024 | IAS-EAS joint symposium, 92nd EAS Congress 2024

Measures of Glycaemia in CAD patients – How do they differ across regions?

Lars Rydén

May 28, 2024 | IAS-EAS joint symposium, 92nd EAS Congress 2024

Global Patterns in Lipid Management of CHD Patients – INTERASPIRE

Kausik Ray

May 28, 2024 | IAS-EAS joint symposium, 92nd EAS Congress 2024

Extracellular matrix in atherosclerosis

Thorsten Kessler

May 28, 2024 | Cellular interplay in vascular frailty, 92nd EAS Congress 2024

Fibroblasts in health and vascular ageing

Judith Sluimer

May 28, 2024 | Cellular interplay in vascular frailty, 92nd EAS Congress 2024

Previously unrecognized effect of D-DT / MIF-2 on VSMCs in advanced stages of atherosclerosis

Bishan Yang

May 28, 2024 | Cellular interplay in vascular frailty, 92nd EAS Congress 2024

PRDM16 controls smooth muscle cell fate in atherosclerosis

Josephine M. E. Tan

May 28, 2024 | Cellular interplay in vascular frailty, 92nd EAS Congress 2024

Smooth muscle cell-specific deletion of S100A4 modifies murine atherosclerotic plaques composition

Pascal Azar

May 28, 2024 | Cellular interplay in vascular frailty, 92nd EAS Congress 2024

Risk of pregnancy- and birth-related outcomes in women with familial hypercholesterolemia versus age-matched controls

Karianne Svendsen

May 28, 2024 | 92nd EAS Congress 2024, Precision medicine beyond LDL-cholesterol

Sex-specific plasma-proteome of incident coronary artery disease

Raymond Noordam

May 28, 2024 | 92nd EAS Congress 2024, Precision medicine beyond LDL-cholesterol

Remnant cholesterol, not LDL cholesterol, explains peripheral artery disease risk conferred by apolipoprotein B: a cohort study

Benjamin N. Wadström

May 28, 2024 | 92nd EAS Congress 2024, Precision medicine beyond LDL-cholesterol

Apolipoprotein E concentrations are predictive of recurrent strokes: insights from the SPARCL trial

Gilles Lambert

May 28, 2024 | 92nd EAS Congress 2024, Precision medicine beyond LDL-cholesterol

ASCVD in women: what is different?

Lale Tokgözoğlu

May 28, 2024 | 92nd EAS Congress 2024, Precision medicine beyond LDL-cholesterol

Lipoprotein (a) molecular mechanisms associated with athero-thrombosis: a topic for precision medicine

Gilles Lambert

May 28, 2024 | 92nd EAS Congress 2024, Precision medicine beyond LDL-cholesterol

How should we screen – systematic vs. cascade

Tomas Freiberger

May 28, 2024 | 92nd EAS Congress 2024, Familial hypercholesterolemia (FH) from screening to management

Monogenic vs polygenic hypercholesterolemia

Jacqueline Dron

May 28, 2024 | 92nd EAS Congress 2024, Familial hypercholesterolemia (FH) from screening to management

Impact of loss-of-function in angiopoietin-like 4 on the human phenome

Eloi Gagnon

May 28, 2024 | Assessment of cardiovascular risk and gene editing therapeutics

Deciphering hypobetalipoproteinemia: a liver gateway toward therapeutic opportunities in ASCVD prevention

Bertrand Cariou

May 27, 2024 | 92nd EAS Congress 2024, Plenary 01

Immune and inflammatory mechanisms linking hypertension and atherosclerosis

Tomasz J. Guzik

May 27, 2024 | 92nd EAS Congress 2024, Plenary 01

Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications

Daniela Carnevale

May 27, 2024 | 92nd EAS Congress 2024, Plenary 01

Triglyceride partitioning in the adipose tissue and atherosclerosis

Sander Kersten

May 27, 2024 | Plenary 01

NLA-EAS joint session – Introduction

Kausik Ray,

Daniel Soffer

May 27, 2024 | NLA-EAS Joint Session

Disaggregating the lipid panel – why should I bother?

Christie Ballantyne

May 27, 2024 | NLA-EAS Joint Session

Lp(a) – who to measure and what to do about it?

Florian Kronenberg

May 27, 2024 | Lp(a) Awareness Day, 92nd EAS Congress 2024, NLA-EAS Joint Session

To apoB or not to apoB

Daniel Soffer

May 27, 2024 | 92nd EAS Congress 2024, NLA-EAS Joint Session

LDL-C lowering across the spectrum of dyslipidemias – why it remains the primary target

Kausik Ray

May 27, 2024 | 92nd EAS Congress 2024, NLA-EAS Joint Session

B cells and antibody responses in atherosclerosis

Christoph Binder

May 27, 2024 | 92nd EAS Congress 2024, Immune regulation in atherosclerosis

Lipid receptors shaping immune cell functions in atherosclerosis

Sabine Steffens

May 27, 2024 | 92nd EAS Congress 2024, Immune regulation in atherosclerosis

Aging promotes mast cell activation and antigen presenting capacity in atherosclerosis

Marie Depuydt

May 27, 2024 | 92nd EAS Congress 2024, Immune regulation in atherosclerosis

Age-related alterations of myeloid cell mitochondrial function and mitophagy contribute to the onset of atherosclerosis

Léa Mangin

May 27, 2024 | 92nd EAS Congress 2024, Immune regulation in atherosclerosis

The effect of low-dose Interleukin-2 on the T cell receptor landscape in patients with acute myocardial infarction

Ayden Case

May 27, 2024 | 92nd EAS Congress 2024, Immune regulation in atherosclerosis

Hypobetalipoproteinaemia and Fatty Liver: New Insights

Salvatore Petta

May 27, 2024 | 92nd EAS Congress 2024, Dyslipidemia and steatotic liver disease

Hepatic retromer is critical for systemic cholesterol homeostasis via shaping the endo-lysosomal organization

Bart van de Sluis

May 27, 2024 | 92nd EAS Congress 2024, Dyslipidemia and steatotic liver disease

MicroRNA-26b protects against MASH development and can be efficiently targeted with lipid nanoparticles

Rosanna Huchzermeier

May 27, 2024 | 92nd EAS Congress 2024, Dyslipidemia and steatotic liver disease

Hepatocyte-specific depletion of TorsinA, an AAA+ ATPase, causes decreased VLDL secretion, abnormal lipid droplet accumulation in the ER, and nonalcoholic steatohepatitis in chow fed mice

Henry Ginsberg

May 27, 2024 | 92nd EAS Congress 2024, Dyslipidemia and steatotic liver disease

Midlife cardiovascular risk factors and risk of vascular-related dementia – in high-risk and low-risk prospective cohorts

Ida Juul Rasmussen

May 27, 2024 | 92nd EAS Congress 2024, From epidemiology and biology to clinical decision making

Are one in four individuals metabolically disadvantaged from conception? Effects of nc886 imprinting

Sonja Raji´c

May 27, 2024 | 92nd EAS Congress 2024, From epidemiology and biology to clinical decision making

Underuse of lipid-lowering therapies in 2021 in patients with established atherosclerotic cardiovascular disease (ASCVD): Results from the French nationwide claims database

Matthieu Wargny

May 27, 2024 | 92nd EAS Congress 2024, From epidemiology and biology to clinical decision making

No increased all-cause mortality in patients with genetically verified familial hypercholesterolemia (FH) – an overlooked success story?

Kjetil Retterstøl

May 27, 2024 | 92nd EAS Congress 2024, From epidemiology and biology to clinical decision making

New insight in the diagnosis and the treatments of severe hypertriglyceridemia

Daniel Gaudet

May 27, 2024 | 92nd EAS Congress 2024, Keynote lecture

Lipid lowering therapy in Europe: Where do we stand?

Carlos Aguiar

May 27, 2024 | 92nd EAS Congress 2024, CME session 4

When and how to start lipid lowering therapy: New trials, new learnings

Kausik Ray

May 27, 2024 | 92nd EAS Congress 2024, CME session 4

What is the rationale for the dietary recommendations for fat intake?

Jacob Christensen

May 27, 2024 | 92nd EAS Congress 2024, Diet and Lifestyle in ASCVD prevention

How to obtain healthy weight throughout life and thereby prevent atherosclerotic cardiovascular disease?

Signe S. Torekov

May 27, 2024 | 92nd EAS Congress 2024, Diet and Lifestyle in ASCVD prevention

The changing cellular landscape in plaque dynamics

Minna Kaikkonen-Määttä

May 27, 2024 | 92nd EAS Congress 2024, Mechanisms of plaque evolution in the aging artery

Specific roles for PI3K/mTOR in mechanotransduction during atherosclerosis

Muriel Laffargue

May 27, 2024 | 92nd EAS Congress 2024, Mechanisms of plaque evolution in the aging artery

Endothelial-to-mesenchymal transition contributes to accelerated atherosclerosis during premature aging

Magda Rita Hamczyk

May 27, 2024 | 92nd EAS Congress 2024, Mechanisms of plaque evolution in the aging artery

Forcing myocardin expression in smooth muscle cells reduces atherosclerosis and decreases their modulation into chondromyocytes

Julián Albarrán-Juárez

May 27, 2024 | 92nd EAS Congress 2024, Mechanisms of plaque evolution in the aging artery

Role of the nuclear receptor Rev-erb-α in vascular calcification

Lise Ferri

May 27, 2024 | 92nd EAS Congress 2024, Mechanisms of plaque evolution in the aging artery

Lipid-induced ATF4 signalling impairs macrophage efferocytosis and promotes atherosclerotic plaque necrosis

Manikandan Subramanian

May 27, 2024 | 92nd EAS Congress 2024, Mechanisms of plaque evolution in the aging artery

New insights in the genetics of FH

Mafalda Bourbon

May 27, 2024 | 92nd EAS Congress 2024, Familial hypercholesterolemia - new genetic and molecular aspects

Genetics of FH: from clinical to molecular classification

Alain Carrié

May 27, 2024 | 92nd EAS Congress 2024, Familial hypercholesterolemia - new genetic and molecular aspects

Spectrum of gene variants in patients with heterozygous familial hypercholesterolaemia across world regions: A study by the FHSC

Amany Elshorbagy

May 27, 2024 | 92nd EAS Congress 2024, Familial hypercholesterolemia - new genetic and molecular aspects

Genetic background of hypercholesterolemia in a large cohort of pediatric patients detected through universal screening program

Urša Šuštar

May 27, 2024 | 92nd EAS Congress 2024, Familial hypercholesterolemia - new genetic and molecular aspects

Cardiovascular risk is more important in index cases of familial hypercholesterolemia

Sophie Beliard

May 27, 2024 | 92nd EAS Congress 2024, Familial hypercholesterolemia - new genetic and molecular aspects

Treatment initiation in fh paediatric patients – 1-year follow-up data from the lipigen paediatric group

Manuela Casula

May 27, 2024 | 92nd EAS Congress 2024, Familial hypercholesterolemia - new genetic and molecular aspects

Protection against high-fat diet induced obesity, dyslipidaemia, and fatty liver in a preclinical setting

Umesh Tharehalli

May 27, 2024 | 92nd EAS Congress 2024, Dyslipidemia and steatotic liver disease

Role of MAIT cells in atherosclerosis

Tobias Radecke

May 27, 2024 | 92nd EAS Congress 2024, Immune regulation in atherosclerosis

Mitigating the risk of ASCVD in diabetes with GLP-1RA- How do they work and who benefits?

André J. Scheen

May 26, 2024 | CME session 1, 92nd EAS Congress 2024

The Holy Grail – Weight management therapy to reduce CV events from diet, drugs or surgery

Nick Finer

May 26, 2024 | CME session 1, 92nd EAS Congress 2024

New horizons in the management of diabetic kidney disease

Janaka Karalliedde

May 26, 2024 | CME session 1, 92nd EAS Congress 2024

Get it right the first time: Approach to managing post-acute coronary syndromes LDL-C

Pasquale Perrone Filardi

May 26, 2024 | 92nd EAS Congress 2024, CME session 2

“Fire and Forget” Time to say Goodbye?

Erik Stroes

May 26, 2024 | 92nd EAS Congress 2024, CME session 2

Common myths of low LDL-C: What did we learn from FOURIER-OLE and real world data?

Robert Giugliano

May 26, 2024 | 92nd EAS Congress 2024, CME session 2

How to identify the patient about to have an ACS?

Pasquale Perrone Filardi

May 26, 2024 | 92nd EAS Congress 2024, CME session 3

Trajectory of Cardiovascular Risk for ASCVD patients: How can we change it?

Julia Brandts

May 26, 2024 | 92nd EAS Congress 2024, CME session 3

Need for speed: Impact of lipid lowering therapy on plaque

Stephen Nicholls

May 26, 2024 | 92nd EAS Congress 2024, CME session 3

Opening Ceremony – Welcome

Kausik Ray

May 26, 2024 | 92nd EAS Congress 2024, Opening Ceremony

Anitschkow Lecture

Bart Staels

May 26, 2024 | 92nd EAS Congress 2024, Opening Ceremony

Reduction of cardiovascular risk in people living with obesity

Naveed Sattar

May 8, 2024 | Webinars on-demand, EAS-LatAm webinar series

The link between obesity and cardio-renal injury: Insights into pathophysiology

Marianne Benn

May 8, 2024 | Webinars on-demand, EAS-LatAm webinar series

Overweight and obesity burden: A global and Latin American perspective

José Francisco Kerr Saraiva

May 8, 2024 | Webinars on-demand, EAS-LatAm webinar series

Women and cardiovascular disease

Lale Tokgözoğlu,

Jeanine Roeters van Lennep,

Marianne Benn,

Frida Emanuelsson

March 6, 2024 | Webinars on-demand, Paediatric Lipid Working Group

Commentary on Lipid guidelines in the USA and Europe: A meeting of the minds?

November 30, -0001 | Commentaries, Publication

Optimal cardiovascular health: also good for the brain

November 30, -0001 | Commentaries, Publication

EAS Consensus panel answers the questions on statin safety

November 30, -0001 | Commentaries, Publication

At the end of the ODYSSEY…what now for PCSK9 inhibition in practice?

November 30, -0001 | Commentaries, Publication

Commentary on Peripheral arterial disease (PAD)

November 30, -0001 | Commentaries, Publication

EAS 2016 Innsbruck Highlights

November 30, -0001 | Commentaries, Publication

EAS 2015 Glasgow Highlights

November 30, -0001 | Commentaries, Publication

Lifestyle for CVD prevention: the priority is sustaining change

November 30, -0001 | Commentaries, Publication

Latest from the FHSC registry: take action now for universal cholesterol screening in early life

January 15, 2024 | Commentaries, Publication

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study.

European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration London, UK

January 6, 2024 | Epidemiology of FH, Publication, Paediatric Lipid Working Group

Time to Screen for HoFH in the US

Samuel Gidding,

Christie Ballantyne,

Marina Cuchel,

Sarah de Ferranti,

Lisa Hudgins,

Allsion Jamison,

Mary McGowan,

Amy L Peterson,

Robert D Steiner,

Melissa K. Uveges,

Yunshu Wang

January 1, 2024 | Other, Paediatric Lipid Working Group

Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?

Steve Humphries,

Uma Ramaswami,

Neil Hopper

December 7, 2023 | Screening for FH, Publication, Paediatric Lipid Working Group

Inflammation in a translational perspective

Christoph Binder,

Peter Libby,

Marianne Benn,

Frida Emanuelsson

November 15, 2023 | Webinars on-demand

New perspectives of lipid-lowering therapies

Alberico L. Catapano

November 15, 2023 | Webinars on-demand

Pharmacological therapy in patients with Familial and Multifactorial Chylomicronemia Syndromes

Philippe Moulin

October 15, 2023 | Rare Disease Day, Lipid Clinic Network

Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis.

Nadeem Qureshi,

Bethan Woods,

Rita Neves de Faria,

Pedro Saramago Goncalves,

Edward Cox,

Jo Leonardi Bee,

Laura Condon,

Stephen Weng,

Ralph Akyea,

Barbara Iyen,

Paul Roderick,

Steve Humphries,

William Rowlands,

Melanie Watson,

Kate Haralambos,

Ryan Kenny,

Dev Datta,

Zosia Miedzybrodzka,

Christopher D Byrne,

Joe Kai

October 1, 2023 | Screening for FH, Publication, Paediatric Lipid Working Group

Challenges for Children with FH

Albert Wiegman,

Danique van den Bogert,

Noel Peretti

September 29, 2023 | Rare Disease Day, HoFH Awareness Day, Webinars on-demand, Joint FH Webinar series 2023: Let’s manage FH together

Access to Treatment for HeFH and HoFH

Meral Kayikcioglu,

Cheryl Lichaa,

Neil Johnson

September 28, 2023 | HoFH Awareness Day, Rare Disease Day, Webinars on-demand, Joint FH Webinar series 2023: Let’s manage FH together

Importance of Measuring Lp(a) in patients with HeFH & HoFH

Florian Kronenberg,

Emma Print,

Jeanine Roeters van Lennep

September 27, 2023 | Lp(a) Awareness Day, Rare Disease Day, HoFH Awareness Day, Webinars on-demand, Joint FH Webinar series 2023: Let’s manage FH together

Screening: experience from cascade screening, universal screening and latest insights on screening on the EU level

Tomas Freiberger,

Indy Bangma,

Nicola Bedlington

September 26, 2023 | Rare Disease Day, Webinars on-demand, Joint FH Webinar series 2023: Let’s manage FH together

Genetics in HeFH and HoFH: the latest insights

Mafalda Bourbon,

Thanos Pallidis,

Philippe Moulin

September 25, 2023 | HoFH Awareness Day, Rare Disease Day, Webinars on-demand, Joint FH Webinar series 2023: Let’s manage FH together

Lipid management in Europe the SANTORINI study

Kausik Ray

May 21, 2023 | Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk, 91st EAS Congress 2023

Novel add-on therapeutic options for LDL-C management

Stephen Nicholls

May 21, 2023 | Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk, 91st EAS Congress 2023

Combination lipid-modifying therapy in high- and very-high-risk patients

Luis Masana

May 21, 2023 | Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk, 91st EAS Congress 2023

Bempedoic acid in clinical practice updates from the MILOS study

May 21, 2023 | Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk, 91st EAS Congress 2023

Panel Discussion: Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk

Kausik Ray,

Lale Tokgözoğlu,

Luis Masana,

Stephen Nicholls

May 21, 2023 | Re-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk, 91st EAS Congress 2023

TG vs apo B reduction

Brian Ference

May 21, 2023 | Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?, 91st EAS Congress 2023

Recent trials with Omega 3 lessons to be learned

Alberto Zambon

May 21, 2023 | Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?, 91st EAS Congress 2023

FIBRATES The PROMINENT trial

Kausik Ray

May 21, 2023 | Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?, 91st EAS Congress 2023

EPA Mechanism(s) of action

Chris Packard

May 21, 2023 | Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?, 91st EAS Congress 2023

Panel Discussion: Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?

Kausik Ray,

Lale Tokgözoğlu,

Brian Ference,

Alberto Zambon,

Chris Packard

May 21, 2023 | Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?, 91st EAS Congress 2023

Modern approach to dyslipidemia

Peter Libby

May 22, 2023 | Integrating the many players of cardiovascular risk, 91st EAS Congress 2023

Fatty liver disease; the new kid on the block of cardio-metabolic disorders

Christos Mantzoros

May 22, 2023 | Integrating the many players of cardiovascular risk, 91st EAS Congress 2023

Adipose tissue expandability, lipotoxicity and Metabolic complications

Antonio Vidal-Puig

May 22, 2023 | Integrating the many players of cardiovascular risk, 91st EAS Congress 2023

How can imaging better help define risk in women

Beatriz Lopez-Melgar

May 22, 2023 | ESC/EAS joint session - Image-guided therapy and prevention for ASCVD, 91st EAS Congress 2023

Diabetes Mellitus and Cardiovascular Risk

Maryam Kavousi

May 22, 2023 | ESC/EAS joint session - Image-guided therapy and prevention for ASCVD, 91st EAS Congress 2023

Defining risk with image-based diagnostics

Jes S. Lindholt

May 22, 2023 | ESC/EAS joint session - Image-guided therapy and prevention for ASCVD, 91st EAS Congress 2023

Can imaging guide lipid lowering therapy?

Pamela B. Morris

May 22, 2023 | ESC/EAS joint session - Image-guided therapy and prevention for ASCVD, 91st EAS Congress 2023

Panel Discussion: ESC/EAS joint session – Image-guided therapy and prevention for ASCVD

Lale Tokgözoğlu,

Ana M. Abreu,

Jes S. Lindholt,

Beatriz Lopez-Melgar,

Pamela B. Morris,

Maryam Kavousi

May 22, 2023 | ESC/EAS joint session - Image-guided therapy and prevention for ASCVD, 91st EAS Congress 2023

Therapeutic potential of CD146 extracellular vesicles for the treatment of atherosclerosis

Cléa Dubrou

May 22, 2023 | Leukocytes in dyslipidemia and atherosclerosis, 91st EAS Congress 2023

NLRP3 Inflammasome inhibition by the novel bispecific antibody inflamAb inhibits atherosclerosis in ApoE-deficient mice

Lucie Delfos

May 22, 2023 | Leukocytes in dyslipidemia and atherosclerosis, 91st EAS Congress 2023

MicroRNA-26b as novel regulator of cardio-metabolic diseases

Emiel van der Vorst

May 22, 2023 | Leukocytes in dyslipidemia and atherosclerosis, 91st EAS Congress 2023

Local macrophage proliferation is triggered by intracellular lipid accumulation

Felix Remmersmann

May 22, 2023 | Leukocytes in dyslipidemia and atherosclerosis, 91st EAS Congress 2023

Leukocyte diversity in the atherosclerotic plaque

Alma Vernecke-Madsen

May 22, 2023 | Leukocytes in dyslipidemia and atherosclerosis, 91st EAS Congress 2023

The HDL proteome in obesity – when good particles go rogue

Fiona McGillicuddy

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

The effect of LDL or HDL-associated PCSK9 on platelet aggregation and inflammatory stimulation of endothelial cells, in vitro

Aikaterini N. Tsouka

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

Patients at high cardiovascular risk exhibit dysfunctional HDL particles

Clement Materne

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

Humoral responses against HDL are linked to lipoprotein traits, atherosclerosis, inflammation and pathogenic pathways during early arthritis stages

Javier Rodríguez-Carrio

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

Cellular interactions of HDL

Arnold von Eckardstein

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

Apolipoprotein E defines high-density lipoprotein trafficking in brain endothelial cells

Jérôme Robert

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

PCSK9 interacts with a subspecies of LDL with IDL-like characteristics

Sara Matteucci

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

New insight into the metabolism of apoB-containing lipoproteins

Bruno Verges

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

Lipoprotein retention and atherosclerosis

Jan Borén

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

Lipid profile during the first year of life

Sofie Taageby Nielsen

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

Consequences of total, hepatocyte or intestinal LDL receptor deficiency on dyslipidemia and atherosclerosis progression in mice

Thibaud Sotin

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

Apolipoprotein proteomics for residual lipid-related risk in coronary heart disease

Lukas Schmidt

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

Inverse effects of APOC2 and ANGPTL4 on the conformational dynamics of lid-anchoring structures in lipoprotein lipase

Anni Kumari

May 22, 2023 | New insight in HDL and CVD, 91st EAS Congress 2023

Chemokine signaling in atherosclerosis – from mechanisms to translation

Christian Weber

May 22, 2023 | 91st EAS Congress 2023, Chemokine signaling in atherosclerosis – from mechanisms to translation

The 8 Pillars of Cholesterol Lowering throughout the Life-course

Kausik Ray

May 22, 2023 | 91st EAS Congress 2023, WHF Cholesterol Roadmap- Cholesterol Lowering Throughout the Life-course

Current Roadblocks and Potential Solutions

Raul Santos

May 22, 2023 | 91st EAS Congress 2023, WHF Cholesterol Roadmap- Cholesterol Lowering Throughout the Life-course

Cholesterol Roundtable case study – Stephen

Stephen Nicholls

May 22, 2023 | 91st EAS Congress 2023, WHF Cholesterol Roadmap- Cholesterol Lowering Throughout the Life-course

Cholesterol Roundtable case study

Ana M. Abreu

May 22, 2023 | 91st EAS Congress 2023, WHF Cholesterol Roadmap- Cholesterol Lowering Throughout the Life-course

Panel Discussion: WHF Cholesterol Roadmap – Cholesterol Lowering Throughout the Life-course

Kausik Ray,

Stephen Nicholls,

Raul Santos,

Ana M. Abreu

November 30, -0001 | 91st EAS Congress 2023, WHF Cholesterol Roadmap- Cholesterol Lowering Throughout the Life-course

The patient with high Triglycerides – What should we do now

Raul Santos

May 22, 2023 | 91st EAS Congress 2023, IAS/EAS joint session - Cardiometabolic traits - The next battleground in Atherosclerosis

The Global Epidemic of Obesity and Cardiovascular Disease – Getting to the heart of the problem

Luc van Gaal

May 22, 2023 | 91st EAS Congress 2023, IAS/EAS joint session - Cardiometabolic traits - The next battleground in Atherosclerosis

Diabetes and Atherosclerosis – Where do we stand in CVD Prevention

Linda Mellbin

May 22, 2023 | 91st EAS Congress 2023, IAS/EAS joint session - Cardiometabolic traits - The next battleground in Atherosclerosis

Panel Discussion: IAS/EAS joint session – Cardiometabolic traits – The next battleground in Atherosclerosis

Kausik Ray,

Peter Libby,

Raul Santos,

Luc van Gaal,

Linda Mellbin

May 22, 2023 | 91st EAS Congress 2023, IAS/EAS joint session - Cardiometabolic traits - The next battleground in Atherosclerosis

SIRT3 regulates arginine metabolism during endothelial dysfunction and atherosclerosis

Xiao-Yu Tian

May 22, 2023 | 91st EAS Congress 2023, Vascular homeostasis and calcification

Role of the nuclear receptor REV-ERB-A in vascular calcification

Lise Ferri

May 22, 2023 | 91st EAS Congress 2023, Vascular homeostasis and calcification

Non-canonical functions of autophagy proteins in cardiovascular diseases

Joëlle Magné

May 22, 2023 | 91st EAS Congress 2023, Vascular homeostasis and calcification

Endothelial mechanotransduction in atherosclerosis

Stephan Huveneers

May 22, 2023 | 91st EAS Congress 2023, Vascular homeostasis and calcification

Endothelial cannabinoid receptor 1 upregulation by pro-atherogenic shear stress promotes vascular inflammation

Aishvaryaa Prabhu

May 22, 2023 | 91st EAS Congress 2023, Vascular homeostasis and calcification

Crosstalk between er stress and the NRF2 pathway in chronic kidney disease-associated vascular calcification

Enikő Balogh

May 22, 2023 | 91st EAS Congress 2023, Vascular homeostasis and calcification

The changing landscape of atherosclerosis

Renu Virmani

May 23, 2023 | 91st EAS Congress 2023, Redefining atherogenesis

Stress and the immune system

Filip Swirski

May 23, 2023 | 91st EAS Congress 2023, Redefining atherogenesis

Discovery of multi receptor drugs for metabolic diseases

Mathias Tschöp

May 23, 2023 | 91st EAS Congress 2023, Redefining atherogenesis

Therapeutic targeting of adaptive immunity in atherosclerotic cardiovascular disease

Tian Zhao

May 23, 2023 | 91st EAS Congress 2023, Young fellows' session

The aging of neutrophils is critical for high fat diets-induced metabolic alterations

Ottavia Terenghi

May 23, 2023 | 91st EAS Congress 2023, Young fellows' session

Single-cell T-cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T-cells

Marie Depuydt

May 23, 2023 | 91st EAS Congress 2023, Young fellows' session

Mechanisms of immune checkpoint inhibition and co-stimulatory receptors in atherosclerosis

Esther Lutgens

May 23, 2023 | 91st EAS Congress 2023, Young fellows' session

Malondialdehyde-specific IGM antibodies define residual atherothrombotic risk

Thomas Koller

May 23, 2023 | 91st EAS Congress 2023, Young fellows' session

Induction of lipid-lowering immune reactions by apolipoprotein B-specific T-helper cells in hypercholesterolemic mice

Anton Gisterå

May 23, 2023 | 91st EAS Congress 2023, Young fellows' session

Identification of a PRDM1-regulated T-cell network which controls T-cell driven plaque inflammation in human and mouse atherosclerosis

Sanne Maas

May 23, 2023 | 91st EAS Congress 2023, Young fellows' session

The SANTORINI and HEYMANS registries

Kausik Ray

May 23, 2023 | 91st EAS Congress 2023, EAS/NLA joint symposium - Registry updates

The GOULD registry

Robert Rosenson

May 23, 2023 | 91st EAS Congress 2023, EAS/NLA joint symposium - Registry updates

The EAS FHSC Studies Collaboration – The Global Registry of FH

Antonio J. Vallejo-Vaz

May 23, 2023 | NLA/EAS joint session - Primordial prevention: The neglected topic, 91st EAS Congress 2023

The CASCADE registry

Mary McGowan

May 23, 2023 | 91st EAS Congress 2023, EAS/NLA joint symposium - Registry updates

Panel Discussion: EAS/NLA joint symposium – Registry updates

Kausik Ray,

Robert Rosenson,

Mary McGowan,

Antonio J. Vallejo-Vaz

May 23, 2023 | 91st EAS Congress 2023, EAS/NLA joint symposium - Registry updates

25-hydrocholesterol in macrophages increases inflammation and atherogenesis

Yajaira Suarez

May 23, 2023 | Lipid metabolism and inflammation in CVD

Cholesterol efflux pathways control T cell aging and atherosclerosis

Marit Westerterp

May 23, 2023 | 91st EAS Congress 2023, Lipid metabolism and inflammation in CVD

Linking cellular lipid trafficking profiles of individuals to the outcomes of cholesterol-lowering therapy in the general population

Iryna Hlushchenko

May 23, 2023 | 91st EAS Congress 2023, Lipid metabolism and inflammation in CVD

Myeloid-PCSK0 deficiency improves cardio-protective by regulating AP-1+ macrophages against Acute Myocardinal Infarction

Goo Taeg Oh

May 23, 2023 | 91st EAS Congress 2023, Lipid metabolism and inflammation in CVD

Intracellular proprotein convertase subtilisin/kexin type 9 and inflammation: unveiling the role of extracellular vesicles in atheroma formation

Chiara Macchi

May 23, 2023 | 91st EAS Congress 2023, Lipid metabolism and inflammation in CVD

The anti-inflammatory IncRNA Heat4 interacts with the pro-inflammatory protein IP1 in non-classical monocytes and promotes vascular regeneration

Jasmin Marga Kneuer

May 23, 2023 | 91st EAS Congress 2023, Lipid metabolism and inflammation in CVD

Dual elevated remnant cholesterol and low-grade inflammation in atherosclerotic cardiovascular disease and mortality

Takahito Doi

May 23, 2023 | 91st EAS Congress 2023, Lipid metabolism and inflammation in CVD

Adipose tissue health as a major determinant in cardiovascular disease

Philipp Scherer

May 23, 2023 | 91st EAS Congress 2023, Obesity, adipose tissue and CVD

Calcium-sensing-receptor in adipocytes is a driver of adipose tissue inflammation and thereby seems to exacerbate atherosclerosis development in an obesity mouse model

Svenja Adam

May 23, 2023 | 91st EAS Congress 2023, Obesity, adipose tissue and CVD

Effect of weight loss on human plasma lipidome: a longitudinal study of lipidomic profiles

Rubina Tabassum

May 23, 2023 | 91st EAS Congress 2023, Obesity, adipose tissue and CVD

Epicardial adipose tissue and metabolic markers in dominican type 2 diabetics with preserved cardiac function

Maxima Mendez Castillo

May 23, 2023 | 91st EAS Congress 2023, Obesity, adipose tissue and CVD

Genetic variation in SLC5A2 mimicking SGLT2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose

Louise Ellegaard Bechmann

May 23, 2023 | 91st EAS Congress 2023, Obesity, adipose tissue and CVD

Ceramide-based lipid profiles and the prevalence of type 2 diabetes differ between patients with coronary artery disease and those with peripheral artery disease

Andreas Leiherer

May 23, 2023 | 91st EAS Congress 2023, Obesity, adipose tissue and CVD

Why we should target apoB lowering not TG or remnants

Alberto Zambon

May 23, 2023 | 91st EAS Congress 2023, Triglycerides and CVD: Where do we stand? Pro & Contra

Introduction: TG as marker or target for treatment

May 23, 2023 | 91st EAS Congress 2023, Triglycerides and CVD: Where do we stand? Pro & Contra

Why EPA is the right choice for the high TG patient

Erin D. Michos

May 23, 2023 | 91st EAS Congress 2023, Triglycerides and CVD: Where do we stand? Pro & Contra

Rebuttals: Triglycerides and CVD: Where do we stand? Pro & Contra

Alberto Zambon,

Erin D. Michos

May 23, 2023 | 91st EAS Congress 2023, Triglycerides and CVD: Where do we stand? Pro & Contra

DNMT3A chip-driver mutations ignite the bone marrow

Tsai-sang Dederichs

May 23, 2023 | 91st EAS Congress 2023, Genetic and epigenetic regulatory mechanisms of atherosclerosis

Integration of genetic and clinical data, with single-cell transcriptomics of atherosclerotic plaques identifies novel smooth muscle cell genes

Sampath Narayanan

May 23, 2023 | 91st EAS Congress 2023, Genetic and epigenetic regulatory mechanisms of atherosclerosis

Uncovering impact of obesity on vasculature in organ- and cell-subtype specific manner

Olga Bondareva

May 23, 2023 | 91st EAS Congress 2023, Genetic and epigenetic regulatory mechanisms of atherosclerosis

Genetic regulation of vascular smooth muscle cell function

Mete Civelek

May 23, 2023 | 91st EAS Congress 2023, Genetic and epigenetic regulatory mechanisms of atherosclerosis

Single-cell and spatial characterization of ischemic heart disease and heart failure from ex-vivo biopsies reveals inflammatory and vascular changes in the right atrium

Eloi Schmauch

May 23, 2023 | Genetic and epigenetic regulatory mechanisms of atherosclerosis

Investigation of the role of ANGPTL3 and PCSK9 in regulating the intracellular signaling in liver cells

Valeria Pecce

May 23, 2023 | 91st EAS Congress 2023, Hepatic lipid metabolism and lipoprotein synthesis

Spring is a novel regulator of hepatic lipid metabolism and plasma lipoprotein levels

Noam Zelcer

May 23, 2023 | 91st EAS Congress 2023, Hepatic lipid metabolism and lipoprotein synthesis

Lomitapide hepatic safety: a long term retrospective analysis in patients with homozygous familial hypercholesterolaemia

Arca Marcello

May 23, 2023 | 91st EAS Congress 2023, Hepatic lipid metabolism and lipoprotein synthesis

Involvement of U2-spliceosome in autosomal dominant hypercholesterolemia

Maëlle Jan

May 23, 2023 | 91st EAS Congress 2023, Hepatic lipid metabolism and lipoprotein synthesis

Pemafibrate induces atheroprotection in LDLr-deficient mice through hepatocyte transrepression PPARa activity

Doriane Henry

May 23, 2023 | 91st EAS Congress 2023, Hepatic lipid metabolism and lipoprotein synthesis

Lifestyle intervention in elderly

Jenni Lethtisalo

May 3, 2023 | Lifestyle: from epidemiology to molecular signatures

Is there a role for diet in secondary prevention?

Linda Badimon

May 23, 2023 | 91st EAS Congress 2023, Lifestyle: from epidemiology to molecular signatures

Mediterranean diet preserves kidney function in patients with type 2 diabetes and obesity: from the cordioprev study

Alicia Podadera Herreros

May 23, 2023 | 91st EAS Congress 2023, Lifestyle: from epidemiology to molecular signatures

Methylomic signatures mediate the effect of psychosocial stress on coronary heart disease

Anthony Zannas

May 23, 2023 | 91st EAS Congress 2023, Lifestyle: from epidemiology to molecular signatures

New evidence of modifiable risk factors for alzheimer’s disease

Jiao Luo

May 23, 2023 | 91st EAS Congress 2023, Lifestyle: from epidemiology to molecular signatures

Imaging and reclassification & risk stratification

Khurram Nasir

May 24, 2023 | 91st EAS Congress 2023, Advancing therapy

Single-cell and spatial transcriptomics dissection of coronary artery disease

Manolis Kellis

May 24, 2023 | 91st EAS Congress 2023, Advancing therapy

Harnessing the pleiotropic benefits of SGLT2i and GLP-1RA to reduce cardiovascular risk

Pam Taub

May 24, 2023 | 91st EAS Congress 2023, Advancing therapy

Genetics and clinical presentation of hypolipidemias

Klaus Parhofer

May 24, 2023 | 91st EAS Congress 2023, Genetics of dyslipidemias

Genetics of hypertriglyceridemias

Arca Marcello

May 24, 2023 | 91st EAS Congress 2023, Genetics of dyslipidemias

Combining family history of coronary heart disease and individual genetic predisposition to accurately predict the lifetime risk of major coronary events

Elena Olmastroni

May 24, 2023 | 91st EAS Congress 2023, Genetics of dyslipidemias

How are children and adolescents with familial hypercholesterolaemia detected globally? Analysis from the FHSC registry on over 11,800 participants from 48 countries

Kanika Dharmayat

May 24, 2023 | 91st EAS Congress 2023, Genetics of dyslipidemias

High lipoprotein(a) increases risk of peripheral arterial disease, abdominal aortic aneurysms, and major adverse limb events

Peter Thomas

May 24, 2023 | 91st EAS Congress 2023, Genetics of dyslipidemias

Additive effect of apoe rare variants on the phenotype of familial hypercholesterolemia

Mathilde Di-Filippo

May 24, 2023 | 91st EAS Congress 2023, Genetics of dyslipidemias

Sitosterolemia in iberoamerican countries: new cases and phenotype genotype analysis

Ana Catarina Alves

May 24, 2023 | 91st EAS Congress 2023, Genetics of dyslipidemias

Pro – Diet and nutrition is helpful for LDL-C lowering

Maciej Banach

May 24, 2023 | 91st EAS Congress 2023, Is there a role for diet and nutrition in LDL lowering?

Contra – Diet and nutrition is not helpful for LDL-C

Ulrich Laufs

May 24, 2023 | 91st EAS Congress 2023, Is there a role for diet and nutrition in LDL lowering?

Rebuttals: Is there a role for diet and nutrition in LDL lowering?

Alberico L. Catapano,

Luis Masana,

Maciej Banach,

Ulrich Laufs

May 24, 2023 | 91st EAS Congress 2023, Is there a role for diet and nutrition in LDL lowering?

Lipid management in ACS patients in 2023: a failure or a success?

Ulrich Laufs

May 21, 2023 | 91st EAS Congress 2023, From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACS

Case Study: How effectively can we manage a post-ACS patient with the available LLTs?

Raffaele De Caterina

May 21, 2023 | 91st EAS Congress 2023, From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACS

ACS EuroPath initiative: the power of bringing the right people together

Azfar Zaman

May 21, 2023 | 91st EAS Congress 2023, From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACS

Lipid Quality Indicators and ‘Fire to Target’: a protocol to improve lipid management in ACS patients

Francois Schiele

May 21, 2023 | 91st EAS Congress 2023, From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACS

Panel Discussion: From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACS

Alberico L. Catapano,

J. Wouter Jukema,

Ulrich Laufs,

Azfar Zaman,

Francois Schiele,

Alessandro Sionis

May 21, 2023 | 91st EAS Congress 2023, From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACS

Lipids in elderly

Martin Mortensen

May 22, 2023 | Clinical Seminar - Lipid management throughout a lifetime

Lipids through the female life course

Kirsten Holven

May 22, 2023 | 91st EAS Congress 2023, Clinical Seminar - Lipid management throughout a lifetime

Managing lipids in children?

Albert Wiegman

May 22, 2023 | 91st EAS Congress 2023, Clinical Seminar - Lipid management throughout a lifetime

Targeting inflammation in atherosclerotic cardiovascular disease: What are our options and where do we stand?

Lale Tokgözoğlu

May 23, 2023 | 91st EAS Congress 2023, How can we reduce cardiovascular risk targeting inflammation via IL-6_

How are systemic inflammation and IL-6 implicated in atherosclerosis and its complications?

Peter Libby

May 22, 2023 | 91st EAS Congress 2023, How can we reduce cardiovascular risk targeting inflammation via IL-6_

Inflammatory risk in cardiovascular disease: What do we know?

Alberico L. Catapano

May 22, 2023 | 91st EAS Congress 2023, How can we reduce cardiovascular risk targeting inflammation via IL-6_

Panel Discussion: How can we reduce cardiovascular risk targeting inflammation via IL-6_

Peter Libby,

Alberico L. Catapano,

Lale Tokgözoğlu

May 23, 2023 | 91st EAS Congress 2023, How can we reduce cardiovascular risk targeting inflammation via IL-6_

Panel Discussion: From evidence to action with elevated Lp(a)_ perspectives on clinical implications and testing

Ingo Hilgendorf,

Christie Ballantyne,

Florian Kronenberg

May 23, 2023 | 91st EAS Congress 2023, From evidence to action with elevated Lp(a)_ perspectives on clinical implications and testing

Homozygous familial hypercholesterolaemia: disease overview, goals of treatment and unmet need

Daniel Gaudet

May 23, 2023 | 91st EAS Congress 2023, Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemia

Therapeutic strategies for homozygous familial hypercholesterolaemia: a review of the clinical trial data

Frederick Raal

May 23, 2023 | 91st EAS Congress 2023, Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemia

Real-world experience with anti-ANGPTL3 antibody therapy in adult and adolescent patients with homozygous familial hypercholesterolaemia

Antonio Gallo

May 23, 2023 | 91st EAS Congress 2023, Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemia

Real-world experience with anti-ANGPTL3 antibody therapy in adolescent patients with homzygous familial hypercholesterolaemia

Albert Wiegman

May 23, 2023 | 91st EAS Congress 2023, Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemia

Panel Discussion: Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemia

Winfried März,

Daniel Gaudet,

Frederick Raal,

Antonio Gallo,

Albert Wiegman

May 23, 2023 | 91st EAS Congress 2023, Latest developments and real-world experience in the management of homozygous familial hypercholesterolaemia

Sex differences in Vascular Aging and Atherosclerosis

Erin D. Michos

May 24, 2023 | 91st EAS Congress 2023, The effect of aging on atherosclerosis

Clonal hematopeisis as an age-related risk for atherosclerosis

Ingo Hilgendorf

May 24, 2023 | 91st EAS Congress 2023, The effect of aging on atherosclerosis

Clonal Hematopoiesis and Trained Immunity in Individuals with Obesity

Helin Tercan

May 24, 2023 | 91st EAS Congress 2023, The effect of aging on atherosclerosis

Single-cell RNA sequencing identifies MFSD2B in megakaryocyte progenitors as a regulator of vascular senescence

Seyed Soheil Saeedi Saravi

May 24, 2023 | 91st EAS Congress 2023, The effect of aging on atherosclerosis

Human and murine single-cell RNA-sequencing reveal fibroblast heterogeneity in healthy and diseased vasculature and differential regulation by ageing and serum cholesterol

Judith Sluimer

May 24, 2023 | 91st EAS Congress 2023, The effect of aging on atherosclerosis

Impact of inner mitochondrial protein on dietary lipid metabolism and atherosclerosis progression

Lorenzo Da Dalt

May 24, 2023 | 91st EAS Congress 2023, The effect of aging on atherosclerosis

Reversing the functional- and regenerative capacity of senescent endothelial cells by pharmacological reprogramming

Katrin Kalies

May 24, 2023 | 91st EAS Congress 2023, The effect of aging on atherosclerosis

A multidisciplinary approach: practical solutions from Spain

Alessandro Sionis

May 21, 2023 | 91st EAS Congress 2023, From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACS

Elevated plasma adiponectin in risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction: observational and mendelian randomization studies

Maria Nielsen

May 23, 2023 | 91st EAS Congress 2023, Late Breaker - Clinical

Lipid management in patients with high and very high cardiovascular risk: data from routine clinical practice in europe (SANTORINI study)

Kausik Ray

May 23, 2023 | 91st EAS Congress 2023, Late Breaker - Clinical

Estimating the potential impact of LDL-C lowering through siRNA therapies on population health: a simulation study

Kausik Ray

May 23, 2023 | 91st EAS Congress 2023, Late Breaker - Clinical

Efficacy and safety of the oral PCSK9 macrocyclic peptide inhibitor MK-0616: a phase 2b randomized controlled trial

Alberico L. Catapano

May 23, 2023 | 91st EAS Congress 2023, Late Breaker - Clinical

Panel Discussion: FHSC-Implementing Global Screening Strategies for FH

Samuel Gidding,

Kausik Ray,

Urh Groselj,

Magdalena Daccord

May 23, 2023 | 91st EAS Congress 2023, FHSC-Implementing Global Screening Strategies for FH

Impact of bempedoic acid on cardiovascular events in high risk patients with statin intolerance: the clear outcomes study

Stephen Nicholls

May 23, 2023 | 91st EAS Congress 2023, Late Breaker - Clinical

Variants in LPA are associated with mutation-negative familial hypercholesterolaemia: genome wide association study in the 100,000 genomes project

Marta Futema

May 23, 2023 | 91st EAS Congress 2023, Late Breaker - Clinical

Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients – Results from the efficacy phase of the APH-19 study

Luis Masana

May 23, 2023 | 91st EAS Congress 2023, Late Breaker - Clinical

Randomized, open-label, cross-over, phase-3 study to evaluate efficacy and safety of LIB003 compared with evolocumab in homozygous familial hypercholesterolaemia patients on stable lipid-lowering therapy (LIBerate-HoFH)

Frederick Raal

May 23, 2023 | 91st EAS Congress 2023, Late Breaker - Clinical

Diagnosis of familial hypercholesterolemia in a large cohort of italian genotyped hypercholesterolemic patients

Federica Brucato

May 23, 2023 | 91st EAS Congress 2023, Late Breaker - Clinical

Therapeutic targeting of the LncRNA IMSET suppresses inflammation and atherosclerotic plaque progression

May 22, 2023 | 91st EAS Congress 2023, Late Breaker - Basic Science

The bispecific anti-FGFR1/KLB agonist antibody bFKB1 attenuates non-alcoholic steatohepatitis and atherosclerosis in Ldlr-/-.Leiden mice

José Inia

May 22, 2023 | 91st EAS Congress 2023, Late Breaker - Basic Science

Temporal changes in coronary plaque as assessed by an artificial intelligence based optical coherence tomography (OCT): from the first-in-human trial on dreams 3G scaffold

Hector Garcia-Garcia

May 22, 2023 | 91st EAS Congress 2023, Late Breaker - Basic Science

Smooth muscle cell tracking in atherosclerotic plaques by noninvasive PET/MR imaging

Susanne Feil

May 22, 2023 | 91st EAS Congress 2023, Late Breaker - Basic Science

Cholesterol-induced suppression of Kir2.1 contributes to atherosclerotic plaque development

Natalia Do Couto

May 22, 2023 | 91st EAS Congress 2023, Late Breaker - Basic Science

Caspase 8-dependent inhibition of necroptosis prevents plaque necrotic core formation

Thomas Pilot

May 22, 2023 | Late Breaker - Basic Science

HoFH: Earlier, Lower, Longer

Anja Vogt

May 22, 2023 | 91st EAS Congress 2023, Optimizing Management of HoFH in a Changing Landscape

Prevalence of FH-Causing Variants and Impact on LDL-C Concentration in European, South Asian, and African Ancestry Groups of the UK Biobank-Brief Report.

Jasmine Gratton,

Steve Humphries,

Marta Futema

September 1, 2023 | Genetics of FH, Publication, Paediatric Lipid Working Group

EAS issues ‘call-to-action’ statement on women, lipids, and atherosclerotic cardiovascular disease

November 30, -0001 | Commentaries, Publication

Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society

August 23, 2023 | Publication, Consensus paper

Lipid-lowering therapies in patients with HoFH

Arca Marcello

July 15, 2023 | Lipid Clinic Network

How to diagnose and treat patients with other genetic dislipidaemias

Robert Hegele

June 15, 2023 | Lipid Clinic Network

Typical and atypical sphingolipids

Thorsten Hornemann

June 9, 2023 | EAS AC in Lipidology

Lipotoxicity driven Metabolic associated fatty liver disease

Pedro Rodriguez

June 9, 2023 | EAS AC in Lipidology

Atherosclerosis. Role of Lipotoxicity

Christoph Binder

June 9, 2023 | EAS AC in Lipidology

Lipid mediators and kidney function

Eoin Brennan

June 9, 2023 | EAS AC in Lipidology

Metabolic myocardiopathy. Does it exist? Data from Metabolomics

Christian Schulze

June 9, 2023 | EAS AC in Lipidology

Role of Lipids in the pahogenesis of beta cell failure

Pierre Maechler

June 9, 2023 | EAS AC in Lipidology

Therapies addressed to stop lipotoxicity

Bart Staels

June 9, 2023 | EAS AC in Lipidology

Lipotoxicity – a pathogenic mechanism of cell and organ damage

Jan Borén

June 8, 2023 | EAS AC in Lipidology

Mass Spectrometry lipidomics for the study of metalobic diseases

Gerhard Liebisch

June 8, 2023 | EAS AC in Lipidology

NMR Lipid and inflammation profiles

Núria Amigó

June 8, 2023 | EAS AC in Lipidology

Molecular Imaging in tissues based on mass spektrometry (URV-IISPV-CIBERDEM)

Xavier Correig

June 8, 2023 | Webinars on-demand

Lipid Maps: an essential tool for lipid research

Matthew Conroy

June 8, 2023 | EAS AC in Lipidology

Neuroprostanes derived from radical oxidation of DHA: promising oxylipins for health

Thierry Durand

June 8, 2023 | EAS AC in Lipidology

Sterols: Cholesterol, Ocisterols, Phytosterols

William J. Griffiths

June 8, 2023 | EAS AC in Lipidology

(Lyso)-Phospholipids

Kathrin Engel

June 8, 2023 | EAS AC in Lipidology

A Machine Learning Model to Aid Detection of Familial Hypercholesterolemia.

Jasmine Gratton,

Marta Futema,

Steve Humphries,

Aroon D Hingorani,

Chris Finan,

Amand F Schmidt

May 24, 2023 | Screening for FH, Publication, Paediatric Lipid Working Group

Gene therapy in lipid metabolism and CVD

Sekar Kathiresan

May 24, 2023 | 91st EAS Congress 2023, Advancing therapy

Variability of tendon xanthomas in heterozygous familial hypercholesterolemia and their relation with lipoprotein(a)

Pablo Fernández Corredoira

May 24, 2023 | 91st EAS Congress 2023, FH session 02

Familial hypercholesterolemia in canada: investigating management patterns and clinical outcomes from the FH canada registry

Iulia Iatan

May 24, 2023 | 91st EAS Congress 2023, FH session 02

Achilles tendon thickness assessed by x-ray predicting a pathogenic mutation in familial hypercholesterolemia gene

Hayato Tada

May 24, 2023 | 91st EAS Congress 2023, FH session 02

Identifying new pathways/players in CVD

Stefanie Dimmeler

May 23, 2023 | 91st EAS Congress 2023, Redefining atherogenesis

Harnessing genetics to identify novel mechanisms involved in VLDL production

Steven Farber

May 23, 2023 | 91st EAS Congress 2023, Hepatic lipid metabolism and lipoprotein synthesis

Going beyond LDL-C: why is Lp(a) critical in current clinical practice?

Christie Ballantyne

May 23, 2023 | Lp(a) Awareness Day, 91st EAS Congress 2023, From evidence to action with elevated Lp(a)_ perspectives on clinical implications and testing

What do we need to do? A call to action on Lp(a) testing

Florian Kronenberg

May 23, 2023 | Lp(a) Awareness Day, 91st EAS Congress 2023, From evidence to action with elevated Lp(a)_ perspectives on clinical implications and testing

What have we learnt about Paediatric Screening from the FHSC

Kausik Ray

May 23, 2023 | 91st EAS Congress 2023, FHSC-Implementing Global Screening Strategies for FH

Slovenia Roundtable representative – Roundtable case study

Urh Groselj

May 23, 2023 | 91st EAS Congress 2023, FHSC-Implementing Global Screening Strategies for FH

Advocating for implementation of FH screening Europe wide

Magdalena Daccord

May 23, 2023 | 91st EAS Congress 2023, FHSC-Implementing Global Screening Strategies for FH

Spatial impact on life expectancy does not correct for familial hypercholesterolemia

Xueqi Dong

May 23, 2023 | 91st EAS Congress 2023, FH session 01

FGF-5 uniquely identifies subjects with heterozygous familial hypercholesterolemia: results from a proteomics study

Andrea Baragetti

May 23, 2023 | 91st EAS Congress 2023, FH session 01

Global prevalence of overweight and obesity among paediatric and adult patients with homozygous or heterozygous familial hypercholesterolaemia, and association with coronary artery disease

Amany Elshorbagy

May 23, 2023 | 91st EAS Congress 2023, FH session 01

Evolocumab treatment in paediatric patients with homozygous familial hypercholesterolemia: data from three pooled open-label studies

Frederick Raal

May 23, 2023 | 91st EAS Congress 2023, FH session 01

Lp(a) – Finding the right place

Florian Kronenberg

May 22, 2023 | Lp(a) Awareness Day, Integrating the many players of cardiovascular risk, 91st EAS Congress 2023

Inflammation in the metabolic syndrome

Peter Libby

May 22, 2023 | 91st EAS Congress 2023, IAS/EAS joint session - Cardiometabolic traits - The next battleground in Atherosclerosis

A long-term Perspective on Effectiveness and Safety in HoFH

Arca Marcello

May 22, 2023 | HoFH Awareness Day, 91st EAS Congress 2023, Optimizing Management of HoFH in a Changing Landscape

New evidence in Pediatric HoFH management

Luis Masana

May 22, 2023 | HoFH Awareness Day, 91st EAS Congress 2023, Optimizing Management of HoFH in a Changing Landscape

Panel Discussion: Optimizing Management of HoFH in a Changing Landscape

Anja Vogt,

Arca Marcello,

Luis Masana

May 22, 2023 | HoFH Awareness Day, 91st EAS Congress 2023, Optimizing Management of HoFH in a Changing Landscape

The 2023 Anitschkow Lecture – Personalized Prevention of Atherosclerotic Cardiovascular Disease. A Global Journey from Discovery to Implementation

Stephen Nicholls

May 21, 2023 | Anitschkow lecture, 91st EAS Congress 2023

Update to consensus statement on homozygous familial hypercholesterolaemia

November 30, -0001 | Commentaries, Publication

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

May 3, 2023 | Publication, Consensus paper

EAS Advanced Course – Rare Lipid Disorders – Cologne

Ioanna Gouni-Berthold,

Michelle O'Donoghue,

Robert Hegele,

Sergio Martínez Hervas,

Handrean Soran,

Maciej Banach

April 19, 2023 | Webinars on-demand

How to diagnose and treat patients with metabolic syndrome

Maciej Banach

April 15, 2023 | Lipid Clinic Network

EAS Advanced Course – Rare Lipid Disorders – Spain/Portugal

Pedro Valdivielso,

Sequeira Duarte,

Mafalda Bourbon,

Diogo Cruz,

Daiana Ibarretxe,

Mathilde Di-Filippo,

Eran Leitersdorf,

Francisco Vasques-Nóvoa

April 14, 2023 | Webinars on-demand

Webinar: Update on the impact of nutrition on ASCVD

Philippe Moulin,

Jean Michel Lecerf,

Ramon Estruch

March 30, 2023 | Webinars on-demand

How to diagnose and treat patients with FH

Jeanine Roeters van Lennep

March 15, 2023 | Lipid Clinic Network

Webinar: How to get your message through on social media

Jeanine Roeters van Lennep,

Kevin Jubbal,

Federica Foggaci,

Sergio Kaiser

March 15, 2023 | Webinars on-demand

A deep dive into CLEAR OUTCOMES and its implications

Alberico L. Catapano,

Lale Tokgözoğlu,

Maciej Banach,

Stephen Nicholls,

Ulrich Laufs

March 13, 2023 | Webinars on-demand

EAS Advanced Course – Rare Lipid Disorders – Poland

Maciej Banach,

Bozena Sosnowska,

Marlena Broncel,

Joanna Lewek,

Ewa Starostecka,

Agata Bielecka-Dabrowa,

Matylda Henning,

Renata Rajtar-Salwa

March 11, 2023 | Webinars on-demand

Webinar: How to use social media effectively

Jeanine Roeters van Lennep,

Sergio Martínez Hervas,

Kevin Jubbal,

Meral Kayikcioglu,

Pierre Sabouret

March 8, 2023 | Webinars on-demand

LCN Lp(a) webinar series #5: Round table with the experts – How to use L(a) in practice, from the point of view of the cardiologist, the lipidologist, the diabetologist and the patient

Alberico L. Catapano,

Lale Tokgözoğlu,

Kausik Ray,

Magdalena Daccord

February 27, 2023 | Lp(a) Awareness Day, Webinars on-demand

How does cholesterol burden change the case for investing in Familial Hypercholesterolaemia? A cost-effectiveness analysis.

Rita Neves de Faria,

Pedro Saramago Goncalves,

Edward Cox,

Stephen Weng,

Barbara Iyen,

Ralph Akyea,

Steve Humphries,

Nadeem Qureshi,

Bethan Woods

February 1, 2023 | Clinical studies of atherosclerosis in FH, Publication, Paediatric Lipid Working Group

LCN Lp(a) webinar series #4: Therapeutic approaches – where we stand today and a look to the future

Alberico L. Catapano

January 19, 2023 | Lp(a) Awareness Day, Webinars on-demand

LCN Lp(a) webinar series #3: Recommendations for Lp(a) screening

Erik Stroes,

Alberico L. Catapano

December 20, 2022 | Lp(a) Awareness Day, Webinars on-demand

LCN Lp(a) webinar series #2: Why and how to measure Lp(a)

Florian Kronenberg

November 22, 2022 | Lp(a) Awareness Day, Webinars on-demand

Webinar: Beyond targeting LDL cholesterol the role of remnants in cardiovascular disease

Jan Borén,

Børge Nordestgaard,

Marianne Benn,

Mie Balling,

Frida Emanuelsson

November 17, 2022 | Webinars on-demand

Metabolism of triglyceride-rich lipoproteins and their remnant lipoproteins in health and dyslipidemias

Jan Borén

November 17, 2022 |

Cholesterol and triglycerides in ApoB-containing lipoproteins and risk of myocardial infarction

Mie Balling

November 17, 2022 |

Remnant cholesterol: Cardiovascular disease risk, guidelines, and treatment

Børge Nordestgaard

November 17, 2022 |

EAS Advanced Course – Rare Lipid Disorders – Sweden & Norway

Stefano Romeo,

Kjetil Retterstøl,

Knut Erik Berge,

Gisle Langslet,

Luca Valenti,

Laura Calabresi,

Paolo Parini,

Emil Andreas Asprusten,

Jeanine Roeters van Lennep

November 16, 2022 | Webinars on-demand

Webinar Oct 2022: How to optimize cardiovascular prevention in type 2 diabetic patients at the borders of the guidelines

Philippe Moulin,

Ioanna Gouni-Berthold,

Bruno Verges

October 27, 2022 | Webinars on-demand

LCN Lp(a) webinar series #1: Lp(a) – what it is, and its role in atherosclerosis

Lale Tokgözoğlu

October 20, 2022 | Lp(a) Awareness Day, Webinars on-demand

EAS Advanced Course – Rare Lipid Disorders – France & Switzerland

Alberico L. Catapano,

Mathilde Di-Filippo,

Daniel Gaudet,

Sophie Beliard,

Philippe Moulin,

Christel Tran,

Noel Peretti,

Sybil Charriere,

René Valero,

Michel Farnier

October 14, 2022 | Webinars on-demand

Hypocholesterolemia friend or foe?

Stefano Romeo,

Arca Marcello,

Mathilde Di-Filippo,

Luca Valenti

September 20, 2022 | Webinars on-demand

New consensus statement on lipoprotein(a)

November 30, -0001 | Commentaries, Publication

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

August 29, 2022 | Publication, Consensus paper

Targeting non-coding RNAs

Kathryn Moore

May 25, 2022 | 90th EAS Congress 2022, Plenary 3: From lifestyle to designer therapies

Developing medicines that mimic resistance mutations

Sekar Kathiresan

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

Cell based therapies in atherosclerosis

Megan Levings

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

Novel anti-atherosclerotic MRNA-based therapy

Hana Totary-Jain

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

Etesian: a phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia

Alexis Hofherr

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

Lomitapide in the long-term real-world management of HOFH – effectiveness, tolerability, and hepatic safety data from the pan-european study

Laura D'Erasmo

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

New World of targeted therapies (targets, delivery systems,new molecules) – Discussion and Q&A

Franco Bernini,

Nathan Wong,

Sekar Kathiresan,

Megan Levings,

Hana Totary-Jain,

Alexis Hofherr,

Laura D'Erasmo

May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022

Imaging guided prevention: Hype or real?

Michael Blaha

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Imaging for plaque progression

Stephen Nicholls

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Non-calcific atherosclerotic burden in hefh: the FH-calc study.

Antonio Gallo

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Aortic valve sclerosis in acute myocardial infarction patients and its association with long-term mortality

Veronika Myasoedova

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

OCT imaging of a wide spectrum of culprit plaque morphology features in acute coronary syndromes

Horea-Laurentiu Onea

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Statin treatment dampens arterial wall inflammation assessed with 68GA-dotatate PET/CT

Reindert Oostveen

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Non-alcoholic to metabolic associated fatty liver disease: cardiovascular implications of a change in terminology in patients living with HIV

Paolo Raggi

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Imaging guided management – Discussion and Q&A

Ulf Landmesser,

Oner Ozdogan,

Michael Blaha,

Stephen Nicholls,

Antonio Gallo,

Veronika Myasoedova,

Horea-Laurentiu Onea,

Reindert Oostveen,

Paolo Raggi

May 25, 2022 | Imaging guided management, 90th EAS Congress 2022

Cell senescence in atherosclerosis and vascular ageing

Martin Bennett

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Lipoprotein(A) is a residual cardiovascular risk factor in statin treated stroke survivors: insights from the sparcl trial

Kévin Chemello

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Combining polygenic risk scores to predict myocardial infarction in the canadian longitudinal study on aging

Hasanga Manik Purage

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Clonal hematopoiesis are not associated with an increased systemic inflammation, atherosclerosis nor incidence of atherothrombosis : results from the 3-city study (chip-3c)

Olivier Mansier

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Carotid plaque characteristics predict recurrent ischemic stroke: the plaque at risk (parisk) study

Dianne van Dam-Nolen

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Body mass index and risk of dementia

Liv Nordestgaard

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

Aging, dementia and stroke – Discussion and Q&A

Alexandros Tselepis,

Ruth Frikke-Schmidt,

José J. Fuster,

Martin Bennett,

Hasanga Manik Purage,

Kévin Chemello,

Dianne van Dam-Nolen,

Olivier Mansier,

Liv Nordestgaard

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

HDL: In search for a function – Arnold von Eckardstein

Arnold von Eckardstein

May 25, 2022 | Debate session - HDL: In search for a function, 90th EAS Congress 2022

HDL: In search for a function – Anne Tybjærg-Hansen

Anne Tybjaerg-Hansen

May 25, 2022 | Debate session - HDL: In search for a function, 90th EAS Congress 2022

Debate session – HDL: In search for a function – Discussion and Q&A

Giuseppe Danilo Norata,

Stefano Romeo,

Arnold von Eckardstein,

Anne Tybjaerg-Hansen

May 25, 2022 | Debate session - HDL: In search for a function, 90th EAS Congress 2022

Clonal hematopoiesis affecting cardiovascular health

José J. Fuster

May 25, 2022 | Aging and dementia and stroke, 90th EAS Congress 2022

How does endothelial rewiring contribute to ASCVD?

Jeffrey Kroon

May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022

Atherosclerosis-associated chronic inflammation: the outcome of metabolic imbalances or irregular immune responses?

Chrysoula Boutari

May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022

Macrophage metabolism in atherosclerosis

Laurent Yvan-Charvet

May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022

How does diabetes accelerate atherosclerosis?

Karin Bornfeldt

May 25, 2022 | Young fellows’ session, 90th EAS Congress 2022

Trigylcerides: From systemic to cellular metabolism

Ira Goldberg

May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?

ApoB – friend and foe

Jan Kuivenhoven

May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?

Emerging therapies for dyslipidemia

Daniel Gaudet

May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?

Lp(a): The next frontier

Sotirios Tsimikas

May 24, 2022 | 90th EAS Congress 2022, Plenary 2: Lipoproteins revisited: What has changed ?

LDL disposal: Receptor vs non-receptor

Marina Cuchel

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

Intracellular regulation of lipoprotein receptors

Bart van de Sluis

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

Hepatic SMLR1 ablation fully protects against diet-induced atherosclerosis but causes hepatosteatosis via reduced VLDL secretion

Willemien van Zwol

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

The genetic lack of ANGTPL3 does not alter HDL functionality

Ilenia Minicocci

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

LDL-cholesterol levels and LDL polygenic score in a cohort of patients with clinically diagnosed familial hypercholesterolemia. Data from the lipigen study

Manuela Casula

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

Do triglycerides have an influence on endothelial function detected by laser doppler flowmetry?

Zivile Girkantaite

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

Importance of APOB and non-HDL cholesterol for ischemic stroke is double that of LDL cholesterol

Camilla Johannesen

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

Apo B containing lipoproteins – Discussion and Q&A

Arca Marcello,

Katariina Öörni,

Marina Cuchel,

Bart van de Sluis,

Willemien van Zwol,

Ilenia Minicocci,

Manuela Casula,

Zivile Girkantaite,

Camilla Johannesen

May 24, 2022 | 90th EAS Congress 2022, Apo B containing lipoproteins

Cell metabolism in endothelial cells

Michael Potente

May 24, 2022 | 90th EAS Congress 2022, Endothelial cell biology in atherosclerosis

Lipoprotein(A) does not have a clinically significant arterial or venous prothrombotic effect

Elena Olmastroni

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Estimating the magnitude of LDL-C reduction needed to overcome the increased risk of atherosclerotic cardiovascular events caused by LP(A) to guide clinical management

Brian Ference

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Antagonism of MIR-148A attenuates the progression of atherosclerosis in apobtgapobec-/-LDLR+/- mice

Noemi Rotllan

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Silencing of ANGPTL4 via antisense oligonucleotides effectively reduces plasma triglyceride and glucose levels in mice without causing lymphadenopathy

Stefan Nilsson

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

A pi3kciialpha/primary cilium-dependent autophagy program protects endothelial cells in response to atheroprone shear stress

Muriel Laffargue

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Epigenetics regulate gene expression of metalloprotease-9 and tissue inhibitor of metalloprotease type 2 in acute coronary syndrome

Bruno Baudin

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Cholestyramine perinatal treatment of apoe deficient mice reduces atherosclerotic plaques development in adult offspring

Marina Habib

May 24, 2022 | Late breaker session 2, 90th EAS Congress 2022

Liver specific targeting of ANGPTL4 using a galnac conjugated antisense oligonucleotides approach

Stefan Nilsson

May 24, 2022 |

The role of necroptosis in atherogenesis and plaque stability

Katey Rayner

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

Smooth muscle cells plasticity in plaque stability

Marie-Luce Bochaton-Piallat

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

Gasdermin D deficiency delays atherogenesis but stimulates plaque apoptosis in apoe-/- mice

Pauline Puylaert

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

Lamin A/C expression in hematopoietic cells regulates mouse atherosclerosis: a potential mechanism contributing to age-dependent atherosclerosis

Marta Amorós-Pérez

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

Smooth muscle cell-specific deletion of S100A4 reroutes smooth muscle cell fate and modifies the inflammatory status of murine atherosclerotic lesions

Luis Cardoso dos Santos

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

The epigenetic enzyme DOT1L orchestrates VSMC–monocyte crosstalk to protect against atherosclerosis via the NF-KB pathway

Floriana Farina

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

Understanding 3D culture in smooth muscle cell biology and the modelling of atherosclerosis

Mei Shan Ong

May 24, 2022 | Smooth muscle cell biology and plaque stability, 90th EAS Congress 2022

Lp(a) a causal risk factor for cardiovascular disease

Børge Nordestgaard

May 24, 2022 | IME Session - Should public health recommendations target Lp(a) measurements?, 90th EAS Congress 2022

The patient with high Lp(a)

Elisabeth Steinhagen-Thiessen

May 24, 2022 | IME Session - Should public health recommendations target Lp(a) measurements?, 90th EAS Congress 2022

IME Session – Should public health recommendations target Lp(a) measurements? – Discussion and Q&A

Alberico L. Catapano,

Børge Nordestgaard,

Elisabeth Steinhagen-Thiessen

May 24, 2022 | IME Session - Should public health recommendations target Lp(a) measurements?, 90th EAS Congress 2022

Why do we need primordial prevention?

Lale Tokgözoğlu

May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022

What is the optimal diet to prevent ASCVD?

Kevin Maki

May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022

Physical activity end cardiovascular prevention

Mai-Lis Hellenius

May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022

Premordial prevention – How to make it work?

Anne Carol Goldberg

May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022

NLA/EAS joint session – Primordial prevention: The neglected topic – Discussion and Q&A

Joseph Saseen,

Kausik Ray,

Lale Tokgözoğlu,

Kevin Maki,

Mai-Lis Hellenius,

Anne Carol Goldberg

May 24, 2022 | NLA/EAS joint session - Primordial prevention: The neglected topic, 90th EAS Congress 2022

Deep phenotyping of disease

Chiara Giannarelli

May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here

Vascular response in atherosclerosis: From epigenetics to bone marrow

Eicke Latz

May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here

Imaging and biomarkers: Targeting the right patient for the right treatment

Wolfgang Koenig

May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here

Implementing genetics scores in clinical practice

Amit V. Khera

May 23, 2022 | 90th EAS Congress 2022, Plenary 1: Personalised approach to ASVD: The future is here

Advances in risk estimation

Ian Graham

May 23, 2022 | ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia

What is new in prevention in apparently healthy persons?

Brian Ference

May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia

What is new in secondary prevention?

Ulrich Laufs

May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia

How to implement this personalised approach?

Michal Vrablik

May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia

Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention – Discussion and Q&A

Alberico L. Catapano,

Ian Graham,

Brian Ference,

Ulrich Laufs,

Michal Vrablik

May 23, 2022 | 90th EAS Congress 2022, ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemia

Stratified treatment of ACS

Filippo Crea

May 23, 2022 | 90th EAS Congress 2022, Keynote Lecture

Overall Concept

Kausik Ray

May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update

Implementation today’s key concepts

Raul Santos

May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update

Translating science into policy

Fernando Lanas Zanetti

May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update

Cumulative exposure, estimating benefits of early invention of lifetime risk

Brian Ference

May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update

WHF Session 1: WHF Roadmap on Cholesterol update – Discussion and Q&A

Kausik Ray,

Raul Santos,

Fernando Lanas Zanetti,

Brian Ference

May 23, 2022 | 90th EAS Congress 2022, WHF Session 1: WHF Roadmap on Cholesterol update

Heart healthy cities

Sanjay Rajagopalan

May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?

Air pollution, City Design and Cardiovascular Disease

Thomas Münzel

May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?

Social Vulnerability and Cardiovascular Disease

Khurram Nasir

May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?

Gene environment interaction

Ruth Loos

May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?

IAS/EAS joint session – What is the environment doing to our health? – Discussion and Q&A

Raul Santos,

Stefano Romeo,

Sanjay Rajagopalan,

Thomas Münzel,

Khurram Nasir,

Ruth Loos

May 23, 2022 | 90th EAS Congress 2022, IAS/EAS joint session - What is the environment doing to our health?

The role of PCSK9 in glucose metabolism and cardiac biology

Giuseppe Danilo Norata

May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights

Deciphering PCSK9 function in the intestine

Bertrand Cariou

May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights

PCSK9 modulates cardiac metabolism and impacts HFPEF

Lorenzo Da Dalt

May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights

Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates cholesterol homeostasis and neuroinflammation in cell models of astrocytes and neurons

Bianca Papotti

May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights

Efficacy of a novel PCSK9 inhibitory peptide alone and in combination with an anti-ANGPTL3 monoclonal antibody in a mouse model of atherosclerosis

Bidda Rolin

May 23, 2022 | 90th EAS Congress 2022, PCSK9 – new insights

Can exercise be tailored to address specific risk factors?

Michael Papadakis

May 23, 2022 | 90th EAS Congress 2022, Targeting risk factors with lifestyle

Carbohydrate/fat or caloric restriction on glycaemia and lipids pathways – what do the trials tell us?

Nicola Guess

May 23, 2022 | 90th EAS Congress 2022, Targeting risk factors with lifestyle

The human gut microbiome and personalized nutrition

Nicola Segata

May 23, 2022 | 90th EAS Congress 2022, Targeting risk factors with lifestyle

Platelet activation and inhibition in atherothrombosis and inflammation

Carlo Patrono

May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells

Detailing the role of neutrophils in atherothrombosis

Irene Lang

May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells

TP53-mutant clonal hematopoiesis accelerates experimental atherosclerosis development

Nuria Matesanz

May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells

In vivo detection of urokinase-type plasminogen activator receptor (UPAR) expression in arterial atherogenesis using [64CU]CU-DOTA-AE105 positron emission tomography

Harshvardhan Khare

May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells

Lipoprotein(a) and SARS-COV-2 infections: risk for ischemic heart disease and thromboembolic events

Silvia Di Maio

May 23, 2022 | 90th EAS Congress 2022, Atherothrombosis and myeloid cells

Dietary components and patterns as determinants of cardiovascular risk

Alice Lichtenstein

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Exercise and cardiovascular disease in 2022: When, who and how ?

Patrick Schrauwen

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Environment

Thomas Münzel

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Western-type diet overrules the protective effect of commensal bacteria in atherogenesis

Tess Yntema

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Early life infection is associated with proinflammatory, atherogenic, and diabetogenic metabolomic and lipidomic profiles at 12 months of age

David Burgner

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Microplastic particles induce endothelial activation

Karsten Grote

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Environment and cardiovascular risk – Discussion and Q&A

Dan Gaita,

Jeanine Roeters van Lennep,

Patrick Schrauwen,

Thomas Münzel,

Tess Yntema,

David Burgner,

Karsten Grote

May 23, 2022 | 90th EAS Congress 2022, Environment and cardiovascular risk

Lysosomal acid lipase (LAL) deficiency alters immune cells distribution in mice and humans

Rossella Bellini

May 23, 2022 | 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

Immune-inflammatory proteomics associated with elevated cardiovascular risk in genetically determined familial hypercholesterolemia

Andrea Baragetti

May 23, 2022 | 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK biobank

Jasmine Gratton

May 23, 2022 | 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

Universal screening is an effective strategy for detecting patients with familial hypercholesterolemia

Urša Šuštar

May 23, 2022 | 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

Comparison of different LDL-C genetic risk score in a sample of clinical FH patients

Ana Margarida Medeiros

May 23, 2022 | 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

Is the risk of atherosclerotic cardiovascular disease different between genotype determined or measured LP(a) levels?

Frederica Galimberti

May 23, 2022 | 90th EAS Congress 2022, Free Communication 1 - Genetics of Dyslipidemia

HoFH: where do we stand?

Arca Marcello

May 23, 2022 | 90th EAS Congress 2022, HOFH: new insights in therapeutic approaches

Novel therapeutic options

Daniel Gaudet

May 23, 2022 | 90th EAS Congress 2022, HOFH: new insights in therapeutic approaches

Introduction and case study

Frederick Raal

May 23, 2022 | 90th EAS Congress 2022, HOFH: new insights in therapeutic approaches

Obicetrapib lowers LDL-C in patients on high intensity statins results from the rose trial (nct04753606)

Kausik Ray

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

A first-in-human single ascending dose study of a monoclonal antibody against the ANGPTL3/8 complex in subjects with mixed hyperlipidemia

Daniel Gaudet

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

Genome-wide association study on HDL-mediated cholesterol efflux capacity

Johanna Schachtl-Riess

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

Global perspective of paediatric familial hypercholesterolaemia: analysis from the EAS FHSC registry on over 11,200 children and adolescents with heterozygous familial hypercholesterolaemia from 44 countries

Kanika Dharmayat

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

Effect of genetic susceptibility to common human disorders on plasma lipidome

Rubina Tabassum

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

High cholesterol absorption is associated with increased cardiovascular risk in hemodialysis patients: insights from the aurora study

Günther Silbernagel

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

High blood neutrophil counts and ischemic vascular disease: observational and genetic studies

Jiao Luo

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

Extracellular vesicles in CVD

Felix Jansen

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Systems biology to estimate cardiovascular risk

Manuel Mayr

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

High lipoprotein(a) and systemic inflammation jointly confer additive high risk of atherosclerotic cardiovascular disease and aortic valve stenosis

Peter Thomas

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Maternal inheritance of a genetic mutation for familial hypercholesterolemia predispose to coronary atherosclerosis in adulthood

Florian Mourre

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Prediction of coronary artery disease and major adverse cardiovascular events using clinical and genetic risk scores for cardiovascular risk factors

Julia Ramírez

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Vascular tissue specific mirna profiles reveal novel correlations with risk factors in coronary artery disease

Sabine Bauer

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Comparison of cardiovascular prognosis between triglyceride variability and exposure estimate in diabetic patients

Hyung Joon Joo

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

Non-classical risk factors: Transitioning from association to causality – Discussion and Q&A

Christoph Binder,

Giulia Chiesa,

Felix Jansen,

Manuel Mayr,

Peter Thomas,

Florian Mourre,

Julia Ramírez,

Sabine Bauer,

Hyung Joon Joo

May 23, 2022 | 90th EAS Congress 2022, Non-classical risk factors: Transitioning from association to causality

How can we optimise lipid lowering after acute coronary syndromes?

Lale Tokgözoğlu

May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy

Pragmatic strategies to better implement combination therapies for very high risk patients

Maciej Banach

May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy

How to implement decision algorithms into routine clinical care- experience across Europe

Carlos Escobar Cervantes

May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy

An App to guide clinical care – what is it and how should we use it

Kausik Ray

May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy

Why and how to implement early combination lipid lowering therapy – Discussion and Q&A

Maciej Banach,

Lale Tokgözoğlu,

Carlos Escobar Cervantes,

Kausik Ray

May 23, 2022 | 90th EAS Congress 2022, Why and how to implement early combination lipid lowering therapy

Macrophage plasticity in atherosclerotic plaques

Claudia Monaco

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Modulating T cell immunity in ASCVD

Ziad Mallat

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Deletion of viperin in the hematopoietic system aggravates atherosclerosis

Dimitrios Tsiantoulas

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

JMJD3-deficiency in CD4+ T cells attenuates atherosclerosis by modulating T-cell polarization

Cecilia Bonfiglio

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Immunumometabolic role of sterol element binding protein 1C (SREBP1C) in tregulatory cell function

Fabrizia Bonacina

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Identification of CD8+ T cell PRDM1 in high-risk human plaques and its regulatory role in murine lesion development

Sanne Maas

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Granzyme B+ CD4+ T cells associate with an unstable plaque phenotype in advanced human atherosclerosis

Marie Depuydt

May 23, 2022 | 90th EAS Congress 2022, Modulating immune responses in atherosclerosis

Reductions in VLDL and Remnant Cholesterol through inhibition of ANGPTL3 Protein Synthesis: An Analysis from TRANSLATE-TIMI 70

Nicholas Marston

May 23, 2022 | 90th EAS Congress 2022, Late breaker session 1

Lp(a): What we need to know

Alberico L. Catapano

May 23, 2022 | 90th EAS Congress 2022, Industry Special Lecture

Why measure Lp(a) and how do I interpret it?

Florian Kronenberg

May 23, 2022 | 90th EAS Congress 2022, Industry Special Lecture

Elevated Lp(a) in clinical practice – Implications for managing our patients

Elisabeth Steinhagen-Thiessen

May 23, 2022 | 90th EAS Congress 2022, Industry Special Lecture

Industry Special Lecture – Discussion and Q&A

Alberico L. Catapano,

Florian Kronenberg,

Elisabeth Steinhagen-Thiessen

May 23, 2022 | 90th EAS Congress 2022, Industry Special Lecture

Managing LDL-C through a clinician’s lens – Michal Vrablík

Michal Vrablik

May 23, 2022 | 90th EAS Congress 2022, Industry Breakfast Session

Managing LDL-C through a behavioral lens – Matthew Willcox

Matthew Willcox

May 23, 2022 | 90th EAS Congress 2022, Industry Breakfast Session

Managing LDL-C through a practical lens: A case study

Ingo Hilgendorf

May 23, 2022 | 90th EAS Congress 2022, Industry Breakfast Session

Industrial Breakfast Session – Disussion and Q&A

Michal Vrablik,

Matthew Willcox,

Ingo Hilgendorf

May 23, 2022 | 90th EAS Congress 2022, Industry Breakfast Session

The epidemiology of DM and obesity and risk of ASCVD

Kausik Ray

May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention

Incretin and related pathways and their role in atherosclerosis

Mansoor Husain

May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention

Does targeting incretin pathways impact cardiovascular outcomes

Frederick Raal

May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention

Diabetes, Obesity and Atherosclerosis – New Horizons in ASCVD Prevention – Discussion and Q&A

Lale Tokgözoğlu,

Kausik Ray,

Frederick Raal,

Mansoor Husain

May 22, 2022 | 90th EAS Congress 2022, Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention

What’s been achieved and what more is needed – real world evidence

Kausik Ray

May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?

Using novel therapies in the real world- case studies

Heinz Drexel

May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?

Start with combination therapy and get on with it

Luis Masana

May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?

Slow and sure wins the race- a stepwise approach

Francois Mach

May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?

Implementation of the 2019 lipid guidelines-where are we now? – Discussion and Q&A

Alberico L. Catapano,

Maurizio Averna,

Kausik Ray,

Heinz Drexel,

Luis Masana,

Francois Mach

May 22, 2022 | 90th EAS Congress 2022, Implementation of the 2019 lipid guidelines-where are we now?

The Omega 3 story from nutrition to pharmacology

Aldo Pietro Maggioni

May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?

Are omega 3 made all equal?

Preston Mason

May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?

Recent trials with Omega 3, lessons to be learned

Gabriel Steg

May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?

Omega 3 fatty acids in cardiovascular prevention – Where do we stand? – Discussion and Q&A

Alberico L. Catapano,

Gabriel Steg,

Aldo Pietro Maggioni,

Preston Mason

May 22, 2022 | 90th EAS Congress 2022, Omega 3 fatty acids in cardiovascular prevention - Where do we stand?

Reimagining prevention – Using AI and causal estimates to preserve health?

Brian Ference

May 22, 2022 | 90th EAS Congress 2022, Reimagining population health-the time is now

Reimagining imaging to guide intensity of treatment – who what and how?

Lale Tokgözoğlu

May 22, 2022 | 90th EAS Congress 2022, Reimagining population health-the time is now

Reimagining prevention: the population approach

Kausik Ray

May 22, 2022 | 90th EAS Congress 2022, Reimagining population health-the time is now

Reimagining population health-the time is now – Discussion and Q&A

Erik Stroes,

Marianne Benn,

Brian Ference,

Lale Tokgözoğlu,

Kausik Ray

May 22, 2022 | 90th EAS Congress 2022, Reimagining population health-the time is now

The 2022 Anitschkow Lecture

Børge Nordestgaard

May 22, 2022 | 90th EAS Congress 2022, Opening Ceremony incl. Anitschkow Lecture

Remnant cholesterol, 2022 EAS Anitschkow Lecture

Børge Nordestgaard

May 22, 2022 |

Polygenic risk score in the diagnosis of combind hyperlipidemia

Jacqueline Dron

March 17, 2022 | Webinars on-demand

EAS Advanced Course in Rare Lipid Disorders – Polish Lipid Association

Maciej Banach,

Marcin Gruchala,

Joanna Lewek,

Ewa Starostecka,

Pawel Burchardt,

Malgorzata Mysliwiec,

Agnieszka Mickiewicz

March 1, 2022 | Webinars on-demand

Novel insights into lipoprotein(a): News from Atherosclerosis

November 30, -0001 | Commentaries, Publication

EAS Advanced Course, Rare Lipid Disorders in Turkey. Nadir Lipid Bozuklukları -Türkiye

Lale Tokgözoğlu,

Meral Kayikcioglu,

Oner Ozdogan,

Bugra Ozkan,

Ozcan Basaran,

Yagiz Uresin,

Baris Gungor,

Murat Akova

January 7, 2022 | Webinars on-demand

Prevention and Treatment of Atherosclerosis – Improving State-of-the-Art Management and Search for Novel Targets

January 1, 2022 | Publication, Handbook

How infraclinic atherosclerosis assessment contributes to personalized lipidology

Eric Bruckert,

Stephan Gielen,

Sara Boccalini,

Philippe Moulin

Webinars on-demand

European Atherosclerosis Society Consensus Panel: New Statement on Triglyceride-Rich Lipoproteins and their Remnants

November 30, -0001 | Commentaries, Publication

Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: levelling up access to treatment urgently needed

November 30, -0001 | Commentaries, Publication

EAS Advanced Course in Rare Lipid Disorders – from Vienna

Christoph Binder,

Arnold von Eckardstein,

Yvonne Winhofer-Stockl,

Florian Kronenberg,

Thomas Stulnig,

Thorsten Hornemann,

Albina Nowak

November 26, 2021 | Webinars on-demand

Aligning plasma lipidomics and metabolic studies in lipid metabolism

Jan Borén,

Peter Würtz,

Gerald Watts,

Marianne Benn

Webinars on-demand

Gene-based therapies – the next generation of atherosclerosis treatment

Rosanne M. Crooke,

Kees Hovingh

November 30, -0001 |

Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement

November 8, 2021 | Publication, Consensus paper

EAS Advanced Course – Rare Lipid Disorders – from Lisbon

Alberico L. Catapano,

Francisco Araujo,

Paula Freitas,

Mafalda Bourbon,

Sequeira Duarte,

Børge Nordestgaard,

Shailesh Patel

November 6, 2021 | Webinars on-demand

From genomics to gene expression in cardiovascular disease

Kári Stefánsson,

Minna Kaikkonen-Määttä,

Ruth Loos,

Christoph Binder

Webinars on-demand

Women, dyslipidaemia and atherosclerosis

Lale Tokgözoğlu,

Fabrice Bonnet,

Erin D. Michos,

Jeanine Roeters van Lennep

November 30, -0001 | Webinars on-demand

Fatty Liver and Cardiovascular Disease: Partners in Crime?

Christopher D Byrne,

Stefano Romeo,

Luca Valenti,

Olov Wiklund

Webinars on-demand

Lipids and atherosclerosis in COVID era

Giuseppina Caligiuri,

Alberto Corsini,

Handrean Soran,

Lale Tokgözoğlu

Webinars on-demand

Understanding lipoprotein(a) in cardiovascular disease

Pia Rørbæk Kamstrup,

Alexandros Tselepis,

Massimiliano Ruscica,

Stefano Romeo

October 27, 2021 | Webinars on-demand

EAS Advanced Course in Rare Lipid Disorders – from Copenhagen

Ruth Frikke-Schmidt,

Jan Borén,

Anne Tybjaerg-Hansen,

Børge Nordestgaard,

Knut Erik Berge,

Laura Calabresi,

Dagmar Kratky,

Robert Hegele,

Stephen Young

October 8, 2021 | Webinars on-demand

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

September 30, 2021 | Publication, Guideline

Global Familial Hypercholesterolemia Studies Collaboration (FHSC) highlights the challenges of care

November 30, -0001 | Commentaries, Publication

HoFH – can we move away from apheresis

Frederick Raal

November 30, -0001 | 89th EAS Congress 2021

From risk factors to acute coronary syndrome in women

Lale Tokgözoğlu

November 30, -0001 | 89th EAS Congress 2021

Weight reduction and atherosclerotic benefits ; from actual evidence to future challenges

Luc van Gaal

November 30, -0001 | 89th EAS Congress 2021

Impaired resolution of inflammation – role of lipid mediators

Magnus Back

November 30, -0001 | 89th EAS Congress 2021

Humoral immune responses in the artery wall.

Christoph Binder

November 30, -0001 | 89th EAS Congress 2021

How to optimize CVD risk reduction

Francesco Cosentino

November 30, -0001 | 89th EAS Congress 2021

How to optimize atherothromobotic therapies to reduce CVD risk

Riitta Lassila

November 30, -0001 | 89th EAS Congress 2021

Gender and Cardiovascular Disease

DeLisa Fairweather

November 30, -0001 | 89th EAS Congress 2021

Gender specific risks in women

Jeanine Roeters van Lennep

November 30, -0001 | 89th EAS Congress 2021

Fibrates to date – a bridge too far

Henry Ginsberg

November 30, -0001 | 89th EAS Congress 2021

Exercise inactivity and circadian rhythms – re-setting the clock in metabolic disease

Juleen Zierath

November 30, -0001 | 89th EAS Congress 2021

Evolving Concepts- Moving from PPAR to SPARM

Bart Staels

November 30, -0001 | 89th EAS Congress 2021

Dietary polyphenols and arterial stiffness

Guido De Meyer

November 30, -0001 | 89th EAS Congress 2021

Coronary Artery Calcification and its Progression: What Does it Really Mean?

Renu Virmani

November 30, -0001 | 89th EAS Congress 2021

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

September 7, 2021 | Publication

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

September 2, 2021 | Publication, Consensus paper

Lipid Clinics Network targets suboptimal guideline implementation

November 30, -0001 | Commentaries, Publication

EAS Task Force gives practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients

November 30, -0001 | Commentaries, Publication

New and old lipid-lowering drugs

Lale Tokgözoğlu

November 30, -0001 | EAS AC on Epidemiology & Genetics

Genetic disorders of lipid metabolism – with special focus on familial hypercholesterolaemia

Kees Hovingh

November 30, -0001 | EAS AC on Epidemiology & Genetics

The new guidelines for dyslipidaemia

Heinz Drexel

Intro to Clinical Lipidology

The clinical experience

Maciej Banach

Intro to Clinical Lipidology

Ongoing studies

Ulrich Laufs

Intro to Clinical Lipidology

Mendelian randomization

Brian Ference

Intro to Clinical Lipidology

CV disease risk classification

Lale Tokgözoğlu

Intro to Clinical Lipidology

Current available therapies – Statins

Jan Borén

Intro to Clinical Lipidology

Current available therapies – PCSK9 inhibition

Ulrich Laufs

Intro to Clinical Lipidology

Current available therapies – Omega3 & fibrates

Maciej Banach

Intro to Clinical Lipidology

Current available therapies – Ezetimbe

Alberico L. Catapano

Intro to Clinical Lipidology

Course presentations – An Introduction to Clinical Lipidology, October 2019

Lale Tokgözoğlu

Intro to Clinical Lipidology

Bempedoic acid – Mechanism of action

Alberico L. Catapano

Intro to Clinical Lipidology

The role of Dendritic Cells in Atherosclerosis

Clement Cochain

EAS AC VII

T cell subsets in atherosclerosis

Maria Wigren

EAS AC VII

Ontogeny and atherosclerosis pathology of B lymphocytes

Stephen Malin

EAS AC VII

Immunomodulation of atherosclerosis

Daniel F.J. Ketelhuth

EAS AC VII

Exploration and modulation of regulatory T cells in atherosclerosis

Hafid Ait-Oufella

EAS AC VII

Emerging cardiovascular therapies targeting the immune system

Jan Nilsson

EAS AC VII

Circulating Cells and Cardiovascular Risk

Harry Björkbacka

EAS AC VII

The role of new lipid lowering drugs

Kausik Ray

EAS AC on FH

The population burden of FH- The need to close the gap

Kausik Ray

EAS AC on FH

The lipid clinic and organization of FH, the role of different participants in the team

Kjetil Retterstøl

EAS AC on FH

Swedish experience from patient society

Gunnar Karlsson

EAS AC on FH

Genetics of FH mutation and distribution

Stefano Romeo

EAS AC on FH

Diagnosis of FH – Scoring systems and Genetic diagnosis, Polygenic causes of clinical FH

Joep Defesche

EAS AC on FH

Cascade screening introduction and experience from Spain

Pedro Mata

EAS AC on FH

Cascade screening introduction and experience from Czech Republic

Tomas Freiberger

EAS AC on FH

What have Mendelian Randomization studies revealed for cardiovascular disease beyond lipids?

Marianne Benn

EAS AC on Epidemiology & Genetics

Using genetics to predict drug effects and adverse events

Anne Tybjaerg-Hansen

EAS AC on Epidemiology & Genetics

The case of lipoprotein(a) and cardiovascular disease

Pia Rørbæk Kamstrup

EAS AC on Epidemiology & Genetics

The case for triglyceride-rich lipoproteins and cardiovascular disease

Børge Nordestgaard

EAS AC on Epidemiology & Genetics

Global burden of cardiovascular disease and contribution of risk factors

Gregory Roth

EAS AC on Epidemiology & Genetics

Concepts of Mendelian randomization

Shah Ebrahim

EAS AC on Epidemiology & Genetics

Causality of lipid traits for other diseases

Ruth Frikke-Schmidt

EAS AC on Epidemiology & Genetics

Biology of lipid metabolism

Patrick Rensen

EAS AC on Epidemiology & Genetics

2016 ESC-EAS guidelines for the management of dyslipidaemias-risk prediction and treatments targets

Olov Wiklund

EAS AC on Epidemiology & Genetics

Regulation of lipid metabolism by inflammation

Laurent Yvan-Charvet

EAS AC on Dyslipidaemia & Inflammation

LDL retention

Jan Borén

EAS AC on Dyslipidaemia & Inflammation

Innate immunity – Inflammasome

Eicke Latz

EAS AC on Dyslipidaemia & Inflammation

Adaptive Immunity – T cells and B cells

Ziad Mallat

EAS AC on Dyslipidaemia & Inflammation

Plasma lipoproteins and their role in atherogenesis

Jan Borén

EAS AC in Lipidology

PCSK9 inhibitor therapy – The cure for atherosclerosis?

Frederick Raal

EAS AC in Lipidology

PCSK9 Inhibition – HIGHLIGHTS FROM RECENT PUBLICATIONS

Alberico L. Catapano

EAS AC in Lipidology

PCSK9 – From promise to clinical practice

Gilles Lambert

EAS AC in Lipidology

Panel discussion

Faculty Presenter(s)

EAS AC in Lipidology

Lipid lowering therapies – statins

Stephen Nicholls

EAS AC in Lipidology

Lipid guidelines, where we stand?

Alberico L. Catapano

EAS AC in Lipidology

Introduction to the course

Alberico L. Catapano

EAS AC in Lipidology

HDL, non HDL cholesterol and TG – a role in atherosclerosis?

Kausik Ray

November 30, -0001 | EAS AC in Lipidology

Genetics for the identification of therapeutic targets in dyslipidaemia

Brian Ference

EAS AC in Lipidology

Familial hypercholesterolemia detection and treatment and the EAS Initiatives

Kausik Ray

EAS AC in Lipidology

Epidemiology of dyslipidemias focus on the region

Hung-I Yeh

EAS AC in Lipidology

CVD – Epidemiology of the risk factors – the central role of LDL cholesterol

Lale Tokgözoğlu

EAS AC in Lipidology

Combination Therapy with non-Statin lipid lowering therapies

Stephen Nicholls

EAS AC in Lipidology

Closing remarks

Alberico L. Catapano

EAS AC in Lipidology

Clinical Cases Discussion

Faculty Presenter(s)

EAS AC in Lipidology

Will precision medicine help tailor dyslipidemia treatment?

Alberto Zambon

EAS 2017 AC on Precision Medicine in A

Precision Cardiovascular Medicine – an unmet need or just a fashion?

Eran Leitersdorf

EAS 2017 AC on Precision Medicine in A

Nutrigenomics for prevention and treatment of obesity

Judith Aron-Wisnewsky

EAS 2017 AC on Precision Medicine in A

Is there a role for Advanced Atherosclerosis Imaging in targeted cardiovascular therapy?

Erik Stroes

EAS 2017 AC on Precision Medicine in A

Identification of novel targets in Hypertension and priorities for drug development

David Rosenbaum

EAS 2017 AC on Precision Medicine in A

Human Genetics from validation of novel cardiovascular drug targets to molecular diagnosis

Alain Carrié

EAS 2017 AC on Precision Medicine in A

Do Novel Biomarkers improve cardiovascular risk stratification?

Arnold von Eckardstein

EAS 2017 AC on Precision Medicine in A

Can we refine strategy on HDL by new pharmacological approaches?

John Chapman

EAS 2017 AC on Precision Medicine in A

Venous vs. arterial thrombosis

Cihan Ay

EAS 2017 AC on Atherothrombosis

Tissue Factor

Nigel Mackman

EAS 2017 AC on Atherothrombosis

Systemsbiology and cardiovascular disease

Jörg Menche

EAS 2017 AC on Atherothrombosis

Platelets and the vascular wall

Rory Koenen

EAS 2017 AC on Atherothrombosis

Monocytes and atherothrombosis

Johann Wojta

EAS 2017 AC on Atherothrombosis

Mechanisms of plaque rupture and erosion

Gerard Pasterkamp

EAS 2017 AC on Atherothrombosis

Immunothrombosis

Steffen Massberg

EAS 2017 AC on Atherothrombosis

Humoral immunity and thrombosis

Christoph Binder

EAS 2017 AC on Atherothrombosis

Gut microbiome and atherothrombosis

Christoph Reinhardt

EAS 2017 AC on Atherothrombosis

The lipoprotein(a) story – from risk factor to causality to clinical trials

Sotirios Tsimikas

November 30, -0001 | 88th EAS Congress 2020

Global perspectives of cardiovascular disease, and impact of risk factors

Gregory Roth

November 30, -0001 | 88th EAS Congress 2020

Can polygenic scores reach clinical practice?

Anne Tybjaerg-Hansen

November 30, -0001 | 88th EAS Congress 2020

The metabolic basis of FCS

Stefano Romeo

November 30, -0001 | Rare Disease Day, 87th EAS Congress 2019

The immune system – The next game-changer?

Matthias Nahrendorf

November 30, -0001 | 87th EAS Congress 2019

The HDL story – Time to reconsider?

John Chapman

November 30, -0001 | 87th EAS Congress 2019

Clotting factors and atherothrombosis

Hugo Ten Cate

EAS 2017 AC on Atherothrombosis

Clinical aspects of atherothrombosis

Irene Lang

EAS 2017 AC on Atherothrombosis

Antiphospholipid antibodies and thrombosis

Karl Lackner

EAS 2017 AC on Atherothrombosis

Recent evidence for the prevention of atherosclerotic cardiovascular diseases

Petri Kovanen

Basic science perspectives

Lipoprotein Metabolism

Arnold von Eckardstein

Basic science perspectives

Treatment of FH – Diet, statin and statin intolerance

Olov Wiklund

An introduction to FH for clinicians

FH in children

Albert Wiegman

An introduction to FH for clinicians

An introduction to Familial Hypercholesterolaemia for clinicians

Stefano Romeo

An introduction to FH for clinicians

Training Agenda Overview

Alberico L. Catapano

An Introduction to Clinical Lipidology

The new guidelines for dyslipidaemia

Alberico L. Catapano

An Introduction to Clinical Lipidology

Statins, including intolerance

Lale Tokgözoğlu

An Introduction to Clinical Lipidology

PCSK9 Inhibition including Inclisiran

Ulf Landmesser

An Introduction to Clinical Lipidology

Omega 3 and fibrates

Jan Borén

An Introduction to Clinical Lipidology

Management of dyslipidaemic patients in clinical practice

Lale Tokgözoğlu

An Introduction to Clinical Lipidology

Lipoprotein metabolism and the causal role of LDL in atherosclerosis

Jan Borén

An Introduction to Clinical Lipidology

Guidelines – the goals why?

Alberico L. Catapano

An Introduction to Clinical Lipidology

Guidelines – FH patients

Jan Borén

An Introduction to Clinical Lipidology

Guidelines – Diabetic patients

Brian Ference

An Introduction to Clinical Lipidology

Guidelines – Diabetic patients

Heinz Drexel

An Introduction to Clinical Lipidology

Guidelines – ACS & very highrisk patients

Ulrich Laufs

An Introduction to Clinical Lipidology

Guidelines – ACS & very high risk patients

Lale Tokgözoğlu

An Introduction to Clinical Lipidology

Ezetimibe

Heinz Drexel

An Introduction to Clinical Lipidology

EAS Introduction

Lale Tokgözoğlu

An Introduction to Clinical Lipidology

CV disease risk classification

Lale Tokgözoğlu

An Introduction to Clinical Lipidology

Bempedoic Acid – The clinical experience

Ulf Landmesser

An Introduction to Clinical Lipidology

Risk Prediction for Add on Lipid Modulating Therapy

Kausik Ray

November 30, -0001 | 87th EAS Congress 2019

Bempedoic Acid – Mechanism of action

Alberico L. Catapano

An Introduction to Clinical Lipidology

What is the landscape on lipid management today?

Lale Tokgözoğlu

88th EAS Congress 2020

What is the environment doing to cardiovascular health?

Nicole Probst-Hensch

88th EAS Congress 2020

What do we know so far about bempedoic acid?

Kausik Ray

88th EAS Congress 2020

Translating science into guidance on the prevention of cardiovascular disease

Guy De Baker

88th EAS Congress 2020

The value of omega 3 – from biology to clinical practice

Alberto Zambon

88th EAS Congress 2020

The biology of PCSK9

Bertrand Cariou

88th EAS Congress 2020

The Angiopoietin-like proteins, controlling lipoprotein metabolism

Sander Kersten

88th EAS Congress 2020

TG-rich lipoproteins as a risk factor

Ruth Frikke-Schmidt

88th EAS Congress 2020

Modified lipids and lipoproteins

Joseph L. Witztum

November 30, -0001 | 87th EAS Congress 2019

siRNA based approaches targeting hepatic synthesis of PCSK9

Kausik Ray

88th EAS Congress 2020

Risk stratification in very high risk patients is it of value?

Faculty Presenter(s)

88th EAS Congress 2020

Inflammation, Inhibition and Atherothrombosis

Paul Ridker

November 30, -0001 | 87th EAS Congress 2019

Prevention of cardiovascular diseases by glucose lowering drugs

Stefano Del Prato

88th EAS Congress 2020

Position of omega 3 in Guidelines (as second choice after statins)

Christie Ballantyne

88th EAS Congress 2020

New therapeutic approaches

John J. Kastelein

88th EAS Congress 2020

Monoclonal antibody approaches targeting circulating PCSK9

Ulf Landmesser

88th EAS Congress 2020

Implementing systems biology to personalise medicine

Johan Björkegren

88th EAS Congress 2020

Immune modulation in atherosclerosis

Ziad Mallat

88th EAS Congress 2020

Difficult cases to reach goal – Recurrent event on statin

Michel Farnier

88th EAS Congress 2020

Difficult cases to reach goal – FH

Meral Kayikcioglu

88th EAS Congress 2020

Case – Diabetic patient with MI – how to manage?

Dirk Muller-Wieland

88th EAS Congress 2020

Can combination aid adherence ? (fixed dose, intolerance)

Michal Vrablik

88th EAS Congress 2020

Are the new EAS-ESC lipids goals reachable in clinical practice?

Francois Mach

88th EAS Congress 2020

An update on the results of ODYSSEY outcomes

Gabriel Steg

88th EAS Congress 2020

AI in CVD & beyond

Jörg Menche

88th EAS Congress 2020

Behaviour change in CVD prevention

Heinke Englert

88th EAS Congress 2020

Biomarkers predicting CVD

Chris Packard

November 30, -0001 | 87th EAS Congress 2019

Precision nutrition and CVD management

Jogchum Plat

88th EAS Congress 2020

A Journey From Plaque to Pate

Helen Hobbs

November 30, -0001 | 87th EAS Congress 2019

What is the price to pay if we are not at goal?

Alberto Zambon

87th EAS Congress 2019

What is the evidence for upfront combination?

Michel Farnier

87th EAS Congress 2019

The genetic evidence for inhibiting the cholesterol synthesis pathway to control LDL cholesterol

Brian Ference

87th EAS Congress 2019

The genetic burden in CVD

Heribert Schunkert

87th EAS Congress 2019

The criticality of LDL goal attainment

Maciej Banach

87th EAS Congress 2019

System-Level analyses of inflammatory and repair Macrophages reveal an integrated circuitry of lipid and epigenomic changes

Laszlo Nagy

87th EAS Congress 2019

Reduce-It – An in depth analysis

Christie Ballantyne

87th EAS Congress 2019

Reality check – Can we get to Guideline recommended targets?

Kornelia Kotseva

87th EAS Congress 2019

Possibilities for Nutrigenetics and Nutraceuticals in CVD prevention

Jogchum Plat

87th EAS Congress 2019

Physician-Patient relationship – Challenges and opportunities

Lale Tokgözoğlu

87th EAS Congress 2019

Pharmacology of Bempedoic acid

Giuseppe Danilo Norata

87th EAS Congress 2019

PCSK9 inhibition in clinical practice

Francois Mach

87th EAS Congress 2019

Optimising cholesterol lowering treatment – How many times do we learn the same lesson?

Luis Masana

87th EAS Congress 2019

Optimal lipid lowering therapy – New and established therapies

Christie Ballantyne

87th EAS Congress 2019

Omega 3 fatty acids – Biological functions

Alexandros Tselepis

87th EAS Congress 2019

Omega 3 and CV benefit a review of the clinical trials

Aldo Pietro Maggioni

87th EAS Congress 2019

New lipid drugs – Is LDL done, ready for new targets?

Erik Stroes

87th EAS Congress 2019

Microbiome – A New Theory of Atherosclerosis?

Thomas Luscher

87th EAS Congress 2019

Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis

Jan Borén

87th EAS Congress 2019

How good are we in reaching the goals?

Guy De Baker

87th EAS Congress 2019

Estimating risk – What’s new?

Ian Graham

87th EAS Congress 2019

Efficacy and safety of nutraceuticals

Maciej Banach

87th EAS Congress 2019

Different approaches to LDL lowering – An overview of options including nutrition, food supplements, and drug therapy

John Chapman

87th EAS Congress 2019

Current evidence for LDL causality; Goals and targets

Chris Packard

87th EAS Congress 2019

Complex cases in lipid lowering treatment – One simple high intensity cholesterol lowering approach fits them all

Arman Postadzhiyan

87th EAS Congress 2019

Clinical experience with Bempedoic Acid

Christie Ballantyne

87th EAS Congress 2019

Cardiovascular aging and Mitochondia function

Douglas Seals

87th EAS Congress 2019

A deep look to the results of Odyssey outcomes

J. Wouter Jukema

87th EAS Congress 2019

Lessons from epidemiology and environmental CVD risk factors

Salim Yusuf

November 30, -0001 | 86th EAS Congress 2018

Imaging and CVD risk estimation (population studies)

Valentin Fuster

November 30, -0001 | 86th EAS Congress 2018

Dysregulation of hepatic and lipoprotein metabolism in the atherogenic dyslipidemia

Marja-Riitta Taskinen

November 30, -0001 | 86th EAS Congress 2018

Lowering LDL-C for cardiovascular disease

Chris Packard

November 30, -0001 | 85th EAS Congress 2017

Will inhibiting thrombus formation prevent acute coronary syndromes?

Stephan Gielen

86th EAS Congress 2018

Will aggressive LDL reduction prevent atherosclerosis?

Alberico L. Catapano

86th EAS Congress 2018

Why does the diet rich in unsaturated fat protect against cardiovascular disease? Differences between nuts and extra virgin olive oil

Emilio Ros

86th EAS Congress 2018

The role of bile acids in cholesterol homeostasis

Albert K. Groen

86th EAS Congress 2018

The multifaceted aspects of CV prevention – from nutrition to therapy – Chair

Alberico L. Catapano,

Alberto Mello e Silva,

Xavier Pinto

86th EAS Congress 2018

The ideal patient for PCSK9

J. Wouter Jukema

86th EAS Congress 2018

Stress, behavior and cardiovascular disease

Viola Vaccarino

86th EAS Congress 2018

Strategies to treat vulnerable plaques

David Erlinge

86th EAS Congress 2018

Silencing genes, new targets

Sotirios Tsimikas

86th EAS Congress 2018

Shifting concepts in the description of the vulnerable plaque

Gerard Pasterkamp

86th EAS Congress 2018

Science versus reality in long term management – Time for a paradigm shift?

Lale Tokgözoğlu

86th EAS Congress 2018

RNA editing controls atherosclerosis

Stefanie Dimmeler

86th EAS Congress 2018

Reducing cholesterol by dietary means

Eric Bruckert

86th EAS Congress 2018

Reality check – Can we get to goals in guidelines?

Ulrich Laufs

86th EAS Congress 2018

PCSK9 inhibition the clinical evidence

Peter Sever

86th EAS Congress 2018

PCSK9 Inhibition in high risk patients

Gabriel Steg

86th EAS Congress 2018

Patient journey after acute coronary syndromes – can we improve outcomes? – Chair

Peter Toth

86th EAS Congress 2018

Panel Discussion

Faculty Presenter(s)

86th EAS Congress 2018

Optimising therapy through cardiac rehabilitation

Anselm Gitt

86th EAS Congress 2018

Novel therapeutic approaches using antisense inhibition

Joseph L. Witztum

86th EAS Congress 2018

Novel role of a Triglyceride-synthesizing enzyme – DGAT1 at the crossroad between Triglyceride and cholesterol metabolism

Vinay Sachdev

86th EAS Congress 2018

New targets for controlling dyslipidaemias and atherosclerosis – chair

Paolo Parini

86th EAS Congress 2018

Neoatherosclerosis from a pathologist’s point of view

Renu Virmani

86th EAS Congress 2018

Nanomedicine as novel atherosclerosis therapy

Willem J.M Mulder

86th EAS Congress 2018

Molecular and biochemical mechanisms involved in the protective effect of Mediterranean diet against atherosclerosis

Alvaro Hernaez

86th EAS Congress 2018

Mining the blood for new cardiometabolic markers

Robert Gerszten

86th EAS Congress 2018

Lipids, inflammation and CV risk

Erik Stroes

86th EAS Congress 2018

Lipid Signaling pathways in physiology and disease

Peter Tontonoz

86th EAS Congress 2018

Lessons from genetics – risk-score and novel candidates

Brian Ference

86th EAS Congress 2018

LDL and apoB-lipoprotein as causative agents in ASCVD

Chris Packard

86th EAS Congress 2018

Keynote Lecture – Chair

Petri Kovanen

86th EAS Congress 2018

Is there need to revise goals from lipid lowering?

Ulf Landmesser

86th EAS Congress 2018

Incremental value of established therapies for dyslipidaemic patients

Luis Masana

86th EAS Congress 2018

How to control atherogenic dyslipidaemia

Henry Ginsberg

86th EAS Congress 2018

Hospital management after acute coronary syndromes – Is the risk over ?

Jose L Zamorano

86th EAS Congress 2018

High-resolution lipoprotein phenotypes and cardiovascular outcomes

Samia Mora

86th EAS Congress 2018

Genetic regulation of HDL cholesterol levels during sepsis

Liam Brunham

86th EAS Congress 2018

Genes can hurt you to develop CVD beyond classical risk factors

Stefano Romeo

86th EAS Congress 2018

Food4me – the experience

Michael Gibney

86th EAS Congress 2018

Effects of the different dietary fatty acids on health – focus on PUFA n-6. New evidences and controversies

Andrea Poli

86th EAS Congress 2018

Dietary fat vs carbohydrates

Gabriele Riccardi

86th EAS Congress 2018

Diet and CVD the epidemiological view

Salim Yusuf

86th EAS Congress 2018

Development of antisense drug targeting PCSK9

Mariko Harada-Shiba

86th EAS Congress 2018

Defective Inflammation Resolution in Atherosclerosis – Mechanisms and Therapeutic Opportunities

Ira Tabas

86th EAS Congress 2018

Combination therapy – When and how

Michel Farnier

86th EAS Congress 2018

Atherothrombosis; from pathogenesis to treatment

Steffen Massberg

86th EAS Congress 2018

Are we ready to test the Lp(a) Hypothesis?

Sotirios Tsimikas

86th EAS Congress 2018

Apo B containing lipoproteins a better target for CV risk reduction?

Brian Ference

86th EAS Congress 2018

Anti-Inflammatory Therapy for Atherosclerosis – Theory and Practice

Peter Libby

86th EAS Congress 2018

A plasma circulating MIRNAS profile predicts Type 2 Diabetes MELLITUS and Prediabetes – From the cordioprev study

Antonio Camargo

86th EAS Congress 2018

A contemporary approach to dyslipidaemias, PCSK9 inhibition

Ulf Landmesser

86th EAS Congress 2018

Why TG-rich lipoproteins-non-HDL-Cholesterol matter when assessing CVD risk? – Introduction

Kausik Ray

85th EAS Congress 2017

Why TG-rich lipoproteins-non-HDL-Cholesterol matter when assessing CVD risk? – Discussion

Faculty Presenter(s)

85th EAS Congress 2017

Using naturally randomized genetic evidence to understand heritability of coronary artery disease?

Brian Ference

85th EAS Congress 2017

Updates on the guidelines. Which role for nutraceuticals?

Emilio Ros

85th EAS Congress 2017

Typical clinical cases – who may benefit?

Eric Bruckert

85th EAS Congress 2017

The value of generic medicines

Gianni Corrao

85th EAS Congress 2017

The new EAS-ESC Guidelines on diet and lifestyle in cardiovascular prevention

Gabriele Riccardi

85th EAS Congress 2017

The clinical evidence – Meta-analysis of the RCT

Matteo Pirro

85th EAS Congress 2017

The case for immune cells – An expanded cardiovascular continuum

Peter Libby

85th EAS Congress 2017

Temporal versus one-time biomarker measurements

Lars Lind

85th EAS Congress 2017

Summary and introduction of guidelines

Alberico L. Catapano

85th EAS Congress 2017

Secondary prevention

Renata Cifkova

85th EAS Congress 2017

Role of non-coding RNA for cholesterol homeostasis and atherogenesis

Kathryn Moore

85th EAS Congress 2017

Regulation of lipid mobilization and lipoprotein secretion by the intestine

Gary Lewis

85th EAS Congress 2017

Progress in understanding the role of nutrition in prevention of atherosclerosis – Discussion

Faculty Presenter(s)

85th EAS Congress 2017

Progress in understanding the role of nutrition in prevention of atherosclerosis – Chair

Jan Borén

85th EAS Congress 2017

Prognostics in patients with manifest (acute or chronic) CHD

Thomas Luscher

85th EAS Congress 2017

Primary prevention

Guy De Baker

85th EAS Congress 2017

PET-MRI

Marc Dweck

85th EAS Congress 2017

Nordic and Mediterranean diet patterns from the CVD point of view

Ursula Schwab

85th EAS Congress 2017

Microbiome and cardiometabolic disease

Fredrik Bäckhed

85th EAS Congress 2017

Mechanistic insights into innovative therapeutics in lipid lowering in vivo

Henry Ginsberg

85th EAS Congress 2017

Lysosomal acid lipase deficiency – an underdiagnosed and misdiagnosed cause of dyslipidemia and liver dysfunction

Maurizio Averna

85th EAS Congress 2017

Life time exposure to LDL-cholesterol is it the key to CVD risk?

Brian Ference

85th EAS Congress 2017

LDL is causal to atherosclerosis

John Chapman

85th EAS Congress 2017

Large-scale epidemiology assessment of the main determinants of cardiovascular disease

Sarah Lewington

85th EAS Congress 2017

LAL deficiency – Discussion

Faculty Presenter(s)

85th EAS Congress 2017

Introduction to Detecting plaque burden or vulnerable plaque – Which way should we go?

Lale Tokgözoğlu

85th EAS Congress 2017

Introduction to Anitschkow prize winner

Lale Tokgözoğlu

85th EAS Congress 2017

Innate immune response drives atherosclerosis

Mihai Netea

85th EAS Congress 2017

Importance of physical activity in metabolic and cardiovascular health and the influence of obesity and diabetes

Patrick Schrauwen

85th EAS Congress 2017

Hypertriglyceridaemia – ApoC-III and ANGPTL3

Sotirios Tsimikas

85th EAS Congress 2017

How to treat diabetic dyslipidaemia – Introduction

Børge Nordestgaard

85th EAS Congress 2017

How to treat diabetic dyslipidaemia

Alberto Zambon

85th EAS Congress 2017

How to treat diabetic dyslipidaemia

Gerald Watts

85th EAS Congress 2017

How LDL causes inflammation in the artery wall

Göran K. Hansson

85th EAS Congress 2017

Hepatic lipid and lipoprotein metabolism

Marja-Riitta Taskinen

85th EAS Congress 2017

HDL-cholesterol and cardiovascular disease – rethinking our approach

John Chapman

85th EAS Congress 2017

FOURIER – first outcomes data with a PCSK9 inhibitor

Terje R Pedersen

85th EAS Congress 2017

Fibrates in the management of AD and CVD risk

Michal Vrablik

85th EAS Congress 2017

Familial hypercholesterolaemia

Kausik Ray

85th EAS Congress 2017

Enzymatic replacement therapy for lysosomal adic lipase deficiency in adult patients with lysosomal acid lipase deficiency

Reena Sharma

85th EAS Congress 2017

Discussion – What do FOURIER data mean for clinical practice?

Faculty Presenter(s)

85th EAS Congress 2017

Diet and cardiometabolic health

Qi Sun

85th EAS Congress 2017

Demystifying the management of hypertriglyceridemia

Anne Tybjaerg-Hansen

85th EAS Congress 2017

CVD prevention strategies – Discussion

Faculty Presenter(s)

85th EAS Congress 2017

CT angiography

Jason M Tarkin

85th EAS Congress 2017

Combination therapy a better way to treat?

Lale Tokgözoğlu

85th EAS Congress 2017

Circulating miRNA for cardiovascular death prediction

Tanja Zeller

85th EAS Congress 2017

Circadian control of metabolism

Frank A.J.L. Scheer

85th EAS Congress 2017

Chronic kidney disease

Alexandros Tselepis

85th EAS Congress 2017

Brown adipose tissue – a novel target to comBAT cardiometabolic disease

Patrick Rensen

85th EAS Congress 2017

Balancing the fat – lipid droplets and human disease

Robert Farese, Jr

85th EAS Congress 2017

Atherosclerosis regression – linking GLAGOV and FOURIER

Stephen Nicholls

85th EAS Congress 2017

Atherogenic dyslipidemia (AD)

Alberto Zambon

85th EAS Congress 2017

3D ultrasound

Stephen Nicholls

85th EAS Congress 2017

How genes control cholesterol

Michael S Brown

84th EAS Congress 2016

A brief history of cholesterol lowering

Terje R Pedersen

Overview of the role of lipids in atherosclerosis

Petri Kovanen

2019 Intro to Clinical Lipidology

Genetic disorders of lipid metabolism with special focus on familial hypercholesterolaemia

Kees Hovingh

2019 Intro to Clinical Lipidology

An Introduction to Clinical Lipidology

Lale Tokgözoğlu

2019 Intro to Clinical Lipidology

The approach of high – and very high risk patients in the new guidelines

Lale Tokgözoğlu

2019 ESC-EAS Dyslipidaemia Guidelines

New recommendations and concepts in the new guidelines

Alberico L. Catapano

2019 ESC-EAS Dyslipidaemia Guidelines

Management of dyslipidaemias in different clinical settings

Olov Wiklund

2019 ESC-EAS Dyslipidaemia Guidelines

Important aspects related to diet and lifestyle in the new guidelines

Gabriele Riccardi

2019 ESC-EAS Dyslipidaemia Guidelines

Dyslipidaemia treatment in ACS

Lale Tokgözoğlu

2019 ESC-EAS Dyslipidaemia Guidelines

Cardiovascular risk assessment and lipid lowering for patients with DM – what do the guidelines say?

Kausik Ray

2019 ESC-EAS Dyslipidaemia Guidelines

A deep dive into EAS-ESC guidelines for dyslipidaemias

Alberico L. Catapano

ANGPTL 3 what we have learned from genetics?

Arca Marcello

November 30, -0001 | 88th EAS Congress 2020

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

April 13, 2021 | Publication, Consensus paper

Latest European Atherosclerosis Society statement reaffirms commitment to the UN Sustainable Development Goals 2030 Agenda

November 30, -0001 | Commentaries, Publication

Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe

February 16, 2021 | Publication, Consensus paper

SAMSON, SAMS and nocebo effects

November 30, -0001 | Commentaries, Publication

Therapeutic Approaches – The NLA Way

Christie Ballantyne

November 30, -0001 |

Therapeutic Approaches – The EAS way

Alberico L. Catapano

November 30, -0001 |

Targets and goals – The NLA way

Carl E. Orringer

November 30, -0001 |

Targets and goals – The EAS way

Chris Packard

November 30, -0001 |

Should we treat high LDL cholesterol in ´health´ elderly individuals?

November 30, -0001 | Commentaries, Publication

The 2020 Anitschkow Lecture – The Oxidation Hypothesis of Atherosclerosis Revisited – A Pivotal Role of OxPL in Atherosclerosis, NASH and Inflammation

Joseph L. Witztum

October 4, 2020 | 88th EAS Congress 2020

DA VINCI study: Change in approach to cholesterol management will be needed to reduce the implementation gap between guidelines and clinical practice in Europe.

November 30, -0001 | Commentaries, Publication

Residual inflammatory risk: lessons from trials for the future

November 30, -0001 | Commentaries, Publication

HDL markers in cardiovascular risk prediction: ethnicity matters

November 30, -0001 | Commentaries, Publication

Familial hypercholesterolemia: an urgent public health priority

November 30, -0001 | Commentaries, Publication

Homozygous familial hypercholesterolaemia: new hope for getting patients to goal?

November 30, -0001 | Commentaries, Publication

Commentary on Targeting LDL cholesterol: early treatment is key to population health

November 30, -0001 | Commentaries, Publication

Commentary on Quantifying atherogenic lipoproteins – pragmatic guidance from the EAS/EFLM Joint Consensus Initiative

November 30, -0001 | Commentaries, Publication

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

February 13, 2020 | Publication, Consensus paper

Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

January 9, 2020 | Publication, Consensus paper

The Clinician’s Handbook: Case-based advice for clinicians on the role of lipids and lipoproteins in atherosclerosis and cardiovascular disease

January 1, 2020 | Publication, Handbook

Commentary on Rare Dyslipidaemia paper

November 30, -0001 | Commentaries, Publication

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

September 30, 2019 | Publication, Consensus paper

First insights from the EAS Familial Hypercholesterolaemia Collaboration Registry: FH is still underdiagnosed and undertreated

November 30, -0001 | Commentaries, Publication

New ESC/EAS guidelines for dyslipidaemia management published. What’s new?

November 30, -0001 | Commentaries, Publication

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

August 31, 2019 | Publication, Guideline

Highlights from the 87th EAS Congress, 26–29th May 2019

November 30, -0001 | Commentaries, Publication

Commentary on Novel therapeutics specific to lipoprotein(a) Lp(a)

November 30, -0001 | Commentaries, Publication

Commentary on Triglycerides and cardiovascular risk: apolipoprotein B holds the key

November 30, -0001 | Commentaries, Publication

A look back at 2018: What made the news?

November 30, -0001 | Commentaries, Publication

Cholesterol and inflammatory risk: Insights from secondary and primary prevention

November 30, -0001 | Commentaries, Publication

Overview of the current status of familial hypercholesterolaemia care in over 60 countries – The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

October 1, 2018 | Publication

New Joint Consensus Initiative on Quantifying Atherogenic Lipoproteins

November 30, -0001 | Commentaries, Publication

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

July 1, 2018 |

Commentary on Highlights of EAS Congress Lisbon

November 30, -0001 | Commentaries, Publication

The 2018 Anitschkow Lecture – Genetics of cardiovascular disease – from ugly duckling to beautiful swan

Anne Tybjaerg-Hansen

May 5, 2018 | 86th EAS Congress 2018

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

April 27, 2018 | Publication, Consensus paper

Commentary on the highs and lows of cardiovascular disease prevention

November 30, -0001 | Commentaries, Publication

Update on SAMS: Statin-Associated Muscle Symptoms

November 30, -0001 | Commentaries, Publication

ESC/EAS Task Force issues updated clinical guidance for the use of PCSK9 inhibitors

November 30, -0001 | Commentaries, Publication

ESC/EAS Task Force provides practical guidance for PCSK9 inhibitors: who to target, LDL-thresholds, future insights

November 30, -0001 | Commentaries, Publication

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

October 16, 2017 | Publication

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

April 24, 2017 | Publication, Consensus paper

The 2017 Anitschkow Lecture – Hematopoiesis, cholesterol and atherosclerosis

Alan Tall

April 23, 2017 | 85th EAS Congress 2017

Pooling and expanding registries of familial hypercholesterolaemia toassess gaps in care and improve disease management and outcomes:Rationale and design of the global EAS Familial HypercholesterolaemiaStudies Collaboration

December 1, 2016 | Publication

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

October 27, 2016 | Publication, Consensus paper

2016 Joint ESC/EAS Dyslipidaemia Guidelines published

November 30, -0001 | Commentaries, Publication

Not at LDL cholesterol goal? Consider statin responsiveness

November 30, -0001 | Commentaries, Publication

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

April 26, 2016 | Publication, Consensus paper

Familial hypercholesterolaemia: A global call to arms

September 18, 2015 | Publication

Position paper on Paediatric FH from the EAS Consensus panel

November 30, -0001 | Commentaries, Publication

EAS Consensus Panel Statement on Homozygous FH

November 30, -0001 | Commentaries, Publication

Position paper on SAMS from the EAS Consensus panel

November 30, -0001 | Commentaries, Publication

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

May 25, 2015 | Publication

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

February 18, 2015 | Publication, Consensus paper

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

August 21, 2014 | Publication, Consensus paper

The 2014 Anitschkow Lecture

John J. Kastelein

May 31, 2014 | 82nd EAS Congress 2014

Focus on lifestyle: EAS Consensus Panel Position Statement on Phytosterol-added Foods

November 30, -0001 | Commentaries, Publication

EAS Consensus Panel paper: Simplifying the definition of hypertriglyceridaemia

November 30, -0001 | Commentaries, Publication

The Polygenic Nature of Hypertriglyceridaemia: Implications for Definition, Diagnosis and Management

December 23, 2013 | Publication, Consensus paper

Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease

November 23, 2013 | Publication, Consensus paper

Improving the care of high-risk patients: The potential of PCSK9

November 30, -0001 | Commentaries, Publication

New EAS Consensus Statement on FH: Improving the care of FH patients

November 30, -0001 | Commentaries, Publication

HDL function and cardiovascular risk

November 30, -0001 | Commentaries, Publication

The 2013 Anitschkow Lecture

Peter Libby

June 2, 2013 | 81st EAS Congress 2013

Gut microbiota: an environmental risk factor for cardiovascular disease

November 30, -0001 | Commentaries, Publication

Triglyceride-rich lipoproteins and HDL

November 30, -0001 | Commentaries, Publication